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Travellers’ Malaria - studies on epidemiology, chemoprophylaxis 




Malaria is the most important parasitic disease. It is endemie in 105 countries and 
causes an estimated annual 300 million episodes of clinical disease each year 
resulting in more than a million deaths. The World Tourism Organisation estimates 
that approximately 30-50 million people from industrialised countries visit malaria 
endemie areas each year which results in frequent importation of the disease 
estimated at 30,000 cases per annum. One section of this work examined the 
background trends and patterns of imported malaria in non-endemie areas. Data on 
reported cases in industrialised countries for the period 1985-1995 were evaluated 
with incidence, case-fatality rates (CFRs) and malaria attack rates in tourists to 
Kenya as the main outcome measures. The study quantified the reported numbers 
of malarial infections in Europe which showed an increase from 6840 in 1985 to 
7244 in 1995 with a peak incidence of 8438 cases in 1989 due to activities of the 
former USSR in Afghanistan. Over 1000 cases are reported annually in the United 
States mainly in travellers to Central America. The study found that in 
industrialised countries, Plasmodium falciparum accounts for an increasing 
proportion of imported species and CFRs range from 0% to 3.6% with Germany 
showing consistently high rates. Tourists to Kenya had particularly high malaria 
attack rates ranging from 18-207 per 100,000 travellers. Furthermore, settled 
immigrants who return to their country of origin to visit friends and relations were 
identified as a high risk group for contracting malaria.  
 
There are three main protective strategies for travellers: 1) use of effective 
mosquito repellents 2) use of chemoprophylactic drugs in areas of high risk and 3) 
prompt assessment and treatment of malaria symptoms including emergency self-
therapy.  
Three studies in this Habilitation examined the use of chemoprophylactic drugs by 
non-immune travellers. The most recent study of 623 volunteers was the first 
double-blind, randomised, clinical trial ever to concomitantly evaluate the 
tolerability of a1l currently used drugs. This multi-centre study with co-
investigators in Switzerland, Germany and Israel found that a large proportion of 
travellers report real or perceived adverse events (AE) to anti-malarial drugs. 
However, serious adverse events are rare. The combination atovaquone/proguanil 
and the monoprophylaxis doxycycline were the best tolerated arms in the study. 
Users of chloroquine/proguanil had the highest proportion of mild to moderate AE 
(45%, 95%CI 37%-53%) followed by mefloquine (42%, CI 34%-50%), 
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doxycycline (33%, CI 26%-41 %) and atovaquone/proguanil (32%, 24%-40%) 
(p=0.048). Depending on the medication used, 6-12% of travellers will seek 
medical advice for adverse events and 2-5% will stop taking the medication due to 
poor tolerability. The study also identified the adverse event profile of each 
medication and found that a significant proportion of women using mefloquine 
report mild to moderate neuropsychological type AE. Of the four medications 
evaluated, the combination chloroquine/proguanil was most poorly tolerated and 
users reported a high incidence of dermatological AE.  
 
A detailed evaluation of the tolerability of mefloquine during short term 
chemoprophylaxis was performed earlier with 420 travellers. This study was 
designed as a result of a 1989 drug alert issued by the WHO for mefloquine which 
identified key research areas - namely quantification of the AE's associated with 
the drug and the relationship between the AE and the pharmacokinetics of 
mefloquine in particular the influence of mefloquine stereochemistry, total 
mefloquine concentrations and metabolite concentrations on the tolerabillity of the 
drug. The results showed no correlation between the incidence of adverse events 
and the concentrations of total mefloquine, or its enantiomers, or the carboxylic 
acid metabolite. Furthermore, the study proved invaluable in providing detailed 
pharmacokinetic data on a large cohort of non-immune travellers and allowed the 
determination of concentration time curves for mefloquine, its enantiomers and 
metabolite for a variety of age and weight groups. The AE incidence rate in the 
study was 11.2% (7.9% neuropsychological) and individuals reporting AE showed 
mood disturbance which was documented using specialised questionnaires (Profile 
of Mood States questionnaire and the Environmental Symptom Questionaire). In 
an attempt to quantify the impact of these „neuropsychological“ adverse events a 
computerised test battery of psychomotor tests, the Neurobehavioural Evaluation 
System 2 (NES2), was employed. There was no significant decline in test 
performance in those with AE compared to controls suggesting that although such 
AE occur, their performance impact is minimal.  
 
Performance was also a theme of a further study „Tolerance of mefloquine by 
Swissair trainee pilots“ which evaluated the impact of the anti-malarial drug 
mefloquine in the context of airline pilots. This study was conducted because a 
World Health Organisation clause restricted the use of mefloquine 
chemoprophylaxis in individuals requiring fine coordination and spatial 
discrimination. The double-blind, placebo-controlled, cross-over study 
quantitatively assessed the effects of mefloquine, at steady state levels, on 
performance in 23 trainee airline pilots. Flying performance was assessed using a 
simplified flight simulator, psychomotor function was evaluated, sleep and wake 
cycles were monitored with actigraphy, and symptoms and moods were assessed 
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using standardised questionnaires. A postural sway meter recorded sway in three 
test positions. There were no significant differences in any of the test results 
between mefloquine and the placebo comparison group but a non-significant 
reduction in total nocturnal sleep was observed in mefloquine users. No 
performance deficit was documented under laboratory conditions during use of 
mefloquine at steady state levels.  
 
One study from this collection evaluated emergency self-treatment of malaria by 
travellers. This strategy is recommended for low-risk, malaria endemic areas and 
involves the carriage of a malaria treatment for self-administration if fever and flu-
like symptoms occur and prompt medical attention is unavailable within 24 hours. 
Some 1,572 travellers were provided with a malaria emergency „kit“ containing a 
thermometer, guidelines on the diagnosis of malaria, chromatography paper for the 
collection of fingertip blood samples for confirmation of malarial infection and a 
malaria treatment, sulphadoxine/pyrimethamine/mefloquine (Fansimef ®). Some 
10% of the cohort became ill with possible malaria symptoms but two thirds of 
those ill failed to seek medical attention as instructed prior to travel. In total six 
persons 0.5% (or 5% of the „ill“ group) used the emergency treatment but only one 
individual had a confirmed malaria. The study highlighted the problems of actually 
defining guidelines and indications for malaria self-treatment because of the range 
of clinical presentations accompanying malaria. Those who did have the pre-
requisite symptoms often hesitated to use the therapy and thus, there exists a 
potential for under-use of the medication whilst those who did use the medication 
had a low probability of correct self-diagnosis. It was shown that travellers behave 
inappropriately when ill, often contrary to pre-travel advice and that self-diagnosis 
of malaria is unlikely to be correct. Drugs for self-treatment are therefore most 
likely to be over- or under used. However, despite the disadvantages inherent in 
the strategy, the study showed that the approach remains an option for certain types 
of traveller and suggests that newer technologies and educational approaches could 
improve the usefulness of this recommendation.  
 
In summary, this collection of studies establishes a scientific basis for „travellers’ 
malaria.“ It provides an epidemiological overview of imported malaria, detailed 
evaluations of the tolerability of drugs used for chemoprophylaxis and a critical 
assessment of the strategy of emergency self-treatment. The studies serve as 
evidence-based, reference studies for the BAG, WHO and CDC in the formulation 
of guidelines to protect those journeying to malaria endemic areas. 
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Imported malaria (1985–95): trends
and perspectives
P. Muentener,1 P. Schlagenhauf,2 & R. Steffen3
Malaria is frequently imported into nonendemic industrialized areas. In this study we collated data on the reported
malaria cases in industrialized countries during the period 1985–95, with the object of identifying trends and
promising strategies. The main outcome measures were incidence, case-fatality rates (CFRs), and attack rates in
tourists returning from Kenya.
Our survey showed gross underreporting and marked heterogeneity in the type and availability of national data.
The total incidence or reported numbers of malaria infections in Europe increased from 6840 in 1985 to 7244 in 1995,
with a peak of 8438 in 1989. The principal importing countries were France, Germany, Italy, and the United Kingdom.
In the former USSR, the reported annual incidence dropped from 1145 in 1989 to 356 in 1990 after cessation of
activities in Afghanistan. Among the imported species of malaria parasite, Plasmodium falciparum was identified in an
increasing proportion, the CFR ranging from 0% to 3.6%, with consistently high rates in Germany. The attack rates
among travellers to Kenya in 1990–95 were high, ranging from 18 to 207 per 100 000 travellers.
Our findings indicate that in industrialized countries malaria is associated with a high CFR and remains a public
health problem. Irregular surveillance and lack of homogeneity in the collected data hinder the assessment of
incidences, risk groups, and the efficacy of chemoprophylaxis.
Voir page 565 le re´sume´ en franc¸ais. En la pa´gina 565 figura un resumen en espan˜ol.
Introduction
The decline or ‘‘natural recession’’ of indigenous
malaria in industrialized countries during the middle
of the 19th century (1) has been attributed to several
factors, such as drainage of swampy areas, better
animal husbandry, improved housing, greater avail-
ability of quinine, and general socioeconomic
improvement. Indeed, the achievement of malaria
eradication on the continent of Europe is viewed as a
major success in the chequered history of global
malaria eradication (2, 3). Nevertheless, malaria
continues to be imported into industrialized areas,
which have been classified as ‘‘malaria free’’, as a
result of human migration and the current tidal wave
of tourist travel to malaria-endemic countries.
A brief glance at travel statistics shows the
spectacular growth in tourism worldwide (4). For
example, in Africa, the main global reservoir of
malaria, there were 17 875 000 international tourist
arrivals in 1993 compared with 750 000 in 1960, an
average annual growth rate of 10.1% (4). The serum of
travellers returning from sub-Saharan Africa showed a
high prevalence of antibodies against the circumspor-
ozoite antigen of Plasmodium falciparum (6–49%,
depending on the type of travel), which indicates a
high rate of malaria infection (5). However, only a
small proportion of travellers to malaria-endemic areas
will actually develop the clinical infection. This
situation poses a double hazard: first, to the individuals
who acquire malaria because the disease may remain
undiagnosed or be incorrectly diagnosed, with
resultant high case-fatality rates; and second, to the
communities these individuals may come into contact
with on their return to Europe, because active malaria
vectors and favourable environmental conditions
could result in local transmission of malaria. Thus,
several outbreaks of autochthonous malaria transmis-
sion have recently been reported in ‘‘malaria-free’’
USA (6–9) and in Europe as a result of the
introduction of infected mosquitos by aircraft (airport
malaria) (10) or contamination of local European
mosquitos that have fed on infected persons returning
from endemic areas (11–13). Global warming is
unlikely to lead to widespread transmission because
the principal factor in the eradication of malaria from
previously endemic areas was not vector eradication
(the anopheles continuing to be present) but improved
living standards, better housing and protection against
mosquito entry.
Quantifying the risks to travellers is necessary
before optimal recommendations can be developed.
The object of our survey was therefore to monitor
imported malaria cases over the period 1985–95 and
to determine the reported incidence of the disease in
industrialized countries, the case-fatality rates
(CFRs), and the incidence among travellers to Kenya
from selected countries.
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Materials and methods
In this retrospective survey, imported malaria describes
an infection that was acquired in an endemic area by
an individual (either a tourist or indigenous native)
but was diagnosed in a nonendemic industrialized
country after development of the clinical disease.
Using addresses provided by WHO, we requested
the persons responsible for malaria surveillance in
each industrialized country concerned to send us a
report on malaria surveillance data for the period
1985–95. Countries that did not respond were
contacted again on two or more occasions by fax
and phone. WHO was also asked to provide any data
on malaria incidence that had been received from
selected countries. In particular, the following key
data were requested:
– the total number of malaria cases reported
annually;
– the species involved and the total number of
P. falciparum cases reported annually;
– the number of fatalities due to malaria infection
reported yearly, from which the CFR was
calculated for P. falciparum infections; and
– the total number of malaria infections imported
annually from Kenya, when available. Kenya was
chosen since the vast majority of travellers to the
country are usually nonimmune tourists and
denominator data are available from the World
Tourism Organization (WTO).
These findings were collated and sent to each country
for verification.
Results
A total of 23 of the 26 (88%) countries surveyed
responded with data, 12 (46%) of them providing all
the requested data. The methods of data collection
varied between countries (Table 1), but most had a
national notification form and notification was
usually mandatory. For the post-1993 period, only
incomplete data were available from the former
Yugoslavia. Many national authorities considered
that their data underestimated the true situation and
that underreporting was rampant. The survey also
showed marked heterogeneity in the quantity and
quality of certain key data such as chemoprophylaxis
used, traveller status, country of origin of infection,
and information on recovery and deaths, which were
infrequently collected despite the recommendations
and proposals for standardized reporting made in
1988 at a meeting of European representatives
responsible for malaria surveillance (14).
Total number of reported malaria cases
A total of 77 683 reported malaria cases were
imported into Europe over the period 1985–95. The
trend in recent years is towards stable or increasing
case numbers (Table 2), the overall increase in the
total of malaria cases reported between 1985 and
1995 being 5.9%. The range varies from 0 (Malta) to
2332 cases (United Kingdom, 1991); 17 countries
reported 200 cases (or fewer) annually, 6 countries
reported 200–1000 cases, and the United Kingdom
reported >1000 cases annually. Outside Europe, only
the USA reported slightly more than 1000 malaria
cases annually. In the former USSR, case numbers
dropped from 1145 in 1989 to 356 in 1990 after
cessation of activities in Afghanistan.
Species profile of imported cases
The proportion of Plasmodium spp. varied consider-
ably between the countries (Table 3). P. falciparum was
the predominant species, accounting annually for
more than 50% of all cases. France showed the
highest proportion of P. falciparum cases, sometimes
exceeding 80%, the lowest (approximately 40%)
being recorded in the USA.
Case-fatality rate profile
Collection of information on deaths due to malaria
was not consistent in the various European countries.
German travellers appeared to have the highest CFR
(mean for 1989–95, 3.6%) (Table 4) in the
industrialized countries. Incomplete data from
Portugal indicated a very high CFR in 1993
(11 deaths among 18 P. falciparum cases, CFR 61%),
but this figure could not be confirmed. The United
Kingdom, in contrast, showed consistently low
CFRs, on average 0.7%.
Attack rates among travellers to Kenya
Travel statistics collated by WTO compared poorly in
some cases with statistics collected by national
bodies. The Swiss national statistics did not correlate
with the WTO tourist statistics. Malaria attack rates in
tourists from various European countries to Kenya
were compared for the years 1990–95 (Table 5). The
highest attack rate, 160 per 100 000, was observed
among Italian travellers in 1993. German travellers
appeared to be particularly at risk with consistently
high attack rates (mean, 128 per 100 000). Low attack
rates (mean, 61 per 100 000) were observed in US
travellers.
Discussion
The 5.9% increase in imported malaria cases (Table 2)
during the 11-year survey period is less than the
proportional increase in travellers to malaria-endemic
regions. Fluctuations in malaria in the endemic areas,
changes in compliance with and efficacy of chemo-
prophylaxis, and artefacts in the reporting of
surveillance data have also probably influenced the
results in Table 2. The observed increased incidence
excludes the former USSR. Between 1981 and 1989 a
total of 7683 cases of malaria were imported into the
USSR from Afghanistan, mainly by demobilized
military personnel (15). Notifications in many
countries show an increase in recent years, but it is
Imported malaria (1985–95): trends and perspectives
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clear that the official notifications often understate
the true position (16). In France it is estimated that
only about 32% of all cases are notified (17). The
problem of inconsistent malaria surveillance in
European countries was reported in 1988 (14), but
little has changed since then. A recent publication by
Legros & Danis has addressed this question in detail
in European countries (18). Attack rates are also likely
to be underestimates as they do not take into account
the cases occurring abroad and underreporting in the
home countries. Some limitations are inherent in our
survey because, in several countries, reporting is
passive, incomplete and biased; however, collection
of surveillance data is important to allow monitoring
of trends.
P. falciparum was the dominant pathogenic
agent but the actual profile of imported species varied
considerably between countries, primarily reflecting
the geographical source of the infection. The United
Kingdom traditionally imported a large proportion of
P. vivax infections through the large number of
immigrants from India and Pakistan (19). However,
in 1988, P. falciparum became the dominant imported
species, reflecting the increased transmission of
P. falciparum in Asia, the changing patterns of traveller
origin, and drug resistance. In the USA, P. falciparum
accounted for less than 50% of all imported
infections because many Americans visit Central
America and Asia rather than tropical Africa. Only
0.4 million American and Canadian travellers visited
Africa, compared with 17 million to Central America
and 2.1 million to Asia (20) — both predominantly
P. vivax transmission areas.
In Italy, imported cases showed a high pre-
valence of P. falciparum infections, mainly because of
African immigrants who visited their country of origin
and became ill with malaria after returning to Italy (21,
22). Data from the Italian Ministry of Health indicate
that malaria from immigrant communities accounts
for an increasing proportion of national figures —
from 14% in 1986 to 40.4% in 1991 (22). Unlike
tourists, returning immigrants who rarely take any
chemoprophylaxis have a high risk of infection, but are
less likely to die from malaria and tend to have
significantly lower parasitaemic levels than those
recorded in travellers. This suggests that despite a
loss of immunity, the presence of some residual
immunological memory has a role in reducing the
severity of the disease (22). Retrospective analyses of
the chemoprophylactic status of persons with malaria
acquired abroad confirm that immigrants rarely use
chemosuppressive drugs (21). Immigrant groups in all
industrialized countries are unlikely to seek medical
advice prior to travel and need to be especially targeted
with advice and protective measures.
Despite medical advances, it has proved to be
difficult to reduce the CFR below 1%. The striking
difference in malaria CFR between countries can only
be partially explained by inadequate surveillance.
Delayed identification of malaria and incorrect
treatment point to deficits in medical awareness
and expertise in the management of this infection.
For the period 1977–86 the average malaria CFR for
Europe as a whole was 1.1% (16). Our survey showed
considerable intercountry variation; Germany had a
high CFR, which could in part be explained by good
mortality reporting in association with poor case
reporting or poor case detection and lack of
awareness about malaria among general practitioners.
According to Zastrow et al. (23, 24), fatalities
occurred almost exclusively from infections acquired
in Africa, mainly among short-stay German tourists
to Kenya. Tourists aged >60 years were especially at
risk. Studies have shown that short-stay tourists to
Kenya were particularly at risk of infection (24, 25).
Tourists who visit Kenya without malaria chemo-
prophylaxis develop malaria at a rate of 1.2% per
Table 1. Type of data collected on imported malaria
by 22 industrialized countries
Type of data
Mandatory Specific Reports Confirmation
notification notification from of parasitea
form laboratories
Europe
Austria yesb yes no P, S
Belgium yesc yes yes P
Denmark yes no no P
Finlandd yes yes yes P
France noe yes yes P
Germany yes yes yes P
Greece yes yes nof P
Irelandg yes no no n/a
Italy yes yes no P
Luxembourg yesh yes no P
Malta yes yes yesi P
Netherlandsg yes yes yes P
Norway yes yes yes P
Poland yes no nok P
Portugalg yes yes no P, S
Spain yes yes yes P, C
Sweden yes no yes P
Switzerland yes yes yes P
United Kingdom yes yes yes P
Elsewhere
Australia yes yes yes P
New Zealand yes yes no P
USA yes yes yes P
a P: parasitology; S: serology; C: clinical; n/a: data not available.
b Since 1994 only.
c Only indigenous infection in the Flemish part of the country.
d Estimates a level of underreporting of 20%.
e Only indigenous infection; estimates a level of underreporting of 55%.
f Hospitals also notify.
g No detection of duplicates and recurrent cases.
h Majority of cases reported by one national clinic.
i Reporting is done by hospital and laboratory.
j Estimates a level of underreporting of 59%.
k Laboratories rarely send data.
Further information on malaria surveillance in EEC countries is given in reference 18.
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month (26, 27). In the absence of international
consensus on recommendations for malaria chemo-
prophylaxis to travellers to Kenya during the period
1990–95, it is possible that the different attack rates
can to some extent be attributed to differences in the
chemoprophylaxis used and/or compliance with
medication and anti-mosquito measures. The pro-
phylactic regimens of choice for travellers to Kenya
were mefloquine (in Switzerland and the USA) or
chloroquine plus proguanil (in Sweden and the
United Kingdom). Table 5 shows that infection rates
were somewhat lower in some countries where
mefloquine was the first-choice regimen, but no
generalization on the effectiveness of the various
regimens can be made due to other factors. After
mefloquine was recommended in the United King-
dom for travellers going to East Africa in 1993, the
rate of imported cases from this area fell substantially
(28). At the same time, the number of malaria patients
who reported taking no chemoprophylaxis has
remained constant. Taking malaria transmission
levels into account, these observations have been
interpreted as evidence for the superior protective
efficacy of mefloquine. Similarly, the 38% decline
among US civilians in the number of falciparum
infections acquired in Africa during 1991–92 has
been attributed in part to increased use of the more
effective mefloquine regimen (28).
Information on compliance with malaria
prophylaxis was only sporadically available in our
survey but other reports stress its importance (29,
30). Approximately 81% of imported malaria infec-
tions among US civilians occurred in those who had
not taken a chemoprophylactic regimen, as recom-
mended by the US Centers for Disease Control and
Prevention (31). Among malaria cases imported to
Germany (1987–91), about 35% of infected indivi-
duals had not used any chemoprophylaxis (24). Pryce
et al. found poor compliance among travellers to
Kenya, with only 16% of cases using currently
Table 2. Number of imported cases of malaria in selected industrialized countries, 1985–95
No. of cases in Annual Total




Austria 82 92 52 83 98 112 111 58 89 75 80 85 932
Belgium 208 298 258 271 272 264 314 249 320 423 304 289 3181
Czechoslovakia 9 11 20 26 28 7 8 7 8 n/aa n/a 14 124
Denmark 128 178 138 142 125 114 110 110 113 136 175 134 1469
Finland 30 28 19 n/aa 52 46 33 39 31 49 31 36 358
France 631 1125 1143 1664 1863 1491 1165 905 769 824 1167 1159 12 747
Germany 591 1137 794 1030 1143 976 900 773 732 830 941 895 9847
Greece 34 39 47 52 48 28 45 29 35 27 24 37 408
Ireland 22 21 28 30 23 12 11 15 9 12 9 17 192
Italy 178 191 287 350 468 521 471 499 688 782 743 471 5178
Luxembourg 7 3 5 n/a 8 7 5 1 4 6 6 5 52
Malta 4 5 2 2 10 3 5 0 4 2 6 4 43
Netherlands 137 167 153 259 244 248 272 179 223 236 312 221 2430
Norway 53 68 47 53 52 60 71 36 76 73 80 61 669
Poland 15 14 16 21 22 21 16 17 27 18 20 19 207
Portugal 62 95 119 113 161 129 108 61 49 67 n/a 96 964
Romania 10 8 13 n/a 5 9 11 19 21 20 30 15 146
Spain 112 179 166 176 118 161 159 154 171 268 263 175 1927
Sweden 140 147 155 172 180 205 149 124 143 160 161 158 1736
Switzerland 200 196 192 322 340 295 322 261 285 310 289 274 3012
United Kingdom 2212 2309 1816 1674 1987 2096 2332 1629 1922 1887 2055 1993 21 919
Former USSR 1918 1686 1323 1580 1145 356 254 188 293 485 548 889 9776
Yugoslavia 57 75 64 53 46 23 18 10 20 n/a n/a 41 366
Total 6840 8072 6857 8073 8438 7184 6890 5363 6032 6690 7244 77 683
Elsewhere
Australia 421 696 574 601 770 874 939 743 670 710 610 692 7608
Canada 314 436 515 307 284 417 674 407 483 n/a 637 447 4474
Japan 53 50 40 48 49 49 52 49 51 64 n/a 51 505
New Zealand n/a n/a n/a n/a 27 32 39 29 58 34 41 37 260
USA 1045 1091 932 1023 1102 1098 1046 910 1275 1014 n/a 1054 10 536
Total 1833 2273 2061 1979 2232 2470 2750 2138 2537 1822 1288 23 383
a n/a: data not available.
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advised regimens (25). Gyorkos et al. found that
compliance with chemoprophylaxis was effective in
reducing the malaria risk (32). Short-stay travellers
often use no protection or inadequate regimens or are
noncompliant with their medication. Deaths occur
more often among individuals who did not use
chemoprophylaxis, and prior chemoprophylaxis
leads to a reduction in the severity of falciparum
malaria (33). Appropriate, effective chemoprophy-
laxis should therefore be recommended for use by
travellers to risk areas and the protective efficacy of
individual prophylactic regimens needs constant
monitoring. The popularity of ‘‘last-minute’’ travel
bargains will increase the number of unprotected
tourists travelling to malaria-endemic areas and lead
to an increased incidence of malaria.
Inconsistent surveillance, lack of homogeneity
in the collected data, and lack of monitoring of drug
responses have been major obstacles to quantifying
the problem of imported malaria in industrialized
countries. Improvements in surveillance and report-
ing would therefore help to quantify incidences,
identify risk groups, and provide an indication of the
prophylactic efficacy of various regimens. A stan-
dardized form for international use in the gathering of
data on malaria cases could be introduced. A priority
for industrialized countries could be the creation of a
Table 3. Percentage of the total number of cases of malaria
caused by Plasmodium falciparum in selected industrialized
countries, 1989--95
% of cases
1989 1990 1991 1992 1993 1994 1995 Annual
average
Austria 64.3 47.3 43.2 34.5 56.2 56.0 57.5 51.3
Belgium 68.0 74.2 68.5 65.1 55.9 n/a n/a 66.3
France 81.1 78.0 n/aa n/a 81.1 84.5 86.0 82.2
Germany 60.7 60.2 58.9 63.3 48.8 67.8 55.9 59.4
Greece 60.4 57.1 44.4 31.0 54.3 37.0 25.0 44.2
Italy 73.7 75.8 74.3 73.5 68.0 72.1 70.9 72.6
Netherlands 68.0 69.0 61.8 61.5 59.6 64.4 55.8 62.9
Portugal 82.6 79.1 79.6 55.7 36.7 n/a n/a 66.8
Spain 59.3 54.0 64.2 55.8 51.5 71.6 60.5 59.6
Sweden 44.4 56.1 42.3 54.0 61.5 75.0 52.2 55.1
Switzerland 49.7 58.3 42.9 54.0 51.6 61.0 65.7 54.7
United 56.2 52.3 56.3 57.4 54.5 62.4 54.1 56.2
Kingdom
USA 40.7 39.0 39.2 32.5 35.8 43.6 n/a 38.5
Annual 62.2 61.6 56.3 53.2 55.1 63.2 58.4
mean
a n/a: data not available.
Table 4. Case fatality rates (CFRs) among cases of Plasmodium falciparum malaria in selected industrialized
countries, 1989–95
1989 1990 1991 1992
Cases Fatalities CFR Cases Fatalities CFR Cases Fatalities CFR Cases Fatalities CFR
% % % %
Austria 63 1 1.59 53 1 1.89 48 0 0.00 20 0 0.00
France 1511 18 1.19 1163 15 1.29 n/aa 20 – n/a 11 –
Germany 694 22 3.17 588 19 3.23 530 10 1.89 489 21 4.29
Greece 29 0 0.00 16 0 0.00 20 0 0.00 9 0 0.00
Italy 345 7 2.03 395 7 1.77 350 6 1.71 367 7 1.91
Netherlands 166 2 1.20 171 1 0.58 168 2 1.19 110 2 1.82
Spain 70 0 0.00 87 0 0.00 102 2 1.96 86 4 4.65
Switzerland 169 2 1.18 172 3 1.74 138 3 2.17 141 2 1.42
United Kingdom 1117 4 0.36 1097 4 0.36 1314 12 0.91 935 11 1.18
USA 448 4 0.89 428 2 0.47 410 0 0.00 296 7 2.36
1993 1994 1995 1989–95
Cases Fatalities CFR Cases Fatalities CFR Cases Fatalities CFR Cases Fatalities CFR
% % % %
Austria 50 2 4.00 42 0 0.00 46 1 2.17 322 5 1.55
France 624 10 1.60 696 12 1.72 1004 13 1.29 4998b 99 1.98
Germany 357 17 4.76 563 28 4.97 526 18 3.42 3747 135 3.60
Greece 19 0 0.00 10 0 0.00 6 0 0.00 109 0 0.00
Italy 468 4 0.85 564 4 0.71 527 5 0.95 3016 40 1.33
Netherlands 133 0 0.00 152 2 1.32 174 2 1.15 1074 11 1.02
Spain 88 1 1.14 192 3 1.56 159 5 3.14 784 15 1.91
Switzerland 147 3 2.04 189 2 1.06 190 2 1.05 1146 17 1.48
United Kingdom 1048 5 0.48 1178 11 0.93 1112 4 0.36 7801 51 0.65
USA 457 8 1.75 442 4 0.90 n/a n/a – 2481b 25 1.01
a n/a: data not available.
b Incomplete data: USA, 6 years; France, 5 years.
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one-page short form with key data variables,
including demographic information (age, sex, name,
nationality, occupation), reason for travel, area of
acquisition of infection, chemoprophylaxis used, date
of diagnosis, species identification, and outcome.
In conclusion, the almost 10 000 imported
malaria cases reported annually illustrate the need to
make tourists and immigrant groups more aware of
the risk of malaria. Cooperation with the travel
industry should lead to the development of pre-
ventive strategies to increase malaria awareness of
travellers. In addition, the medical profession must
be conditioned to consider malaria in the differential
diagnosis of any unexplained fever and to act
appropriately. n
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Re´sume´
Le paludisme importe´ (1985-1995) : tendances et perspectives
Le paludisme est souvent importe´ dans des zones
industrialise´es ou` il n’existe normalement pas a` l’e´tat
ende´mique. L’article donne les re´sultats d’une enqueˆte
qui a consiste´ a` rassembler les donne´es relatives aux cas
de paludisme signale´s dans les pays industrialise´s au
cours de la pe´riode 1985-1995, le but e´tant de de´gager
des tendances et de voir quelles strate´gies sont
prometteuses dans ce domaine. Les principales variables
mesure´es que nous avons examine´es sont l’incidence, le
taux de le´talite´ et le taux d’atteinte chez des touristes au
retour du Kenya.
Notre enqueˆte a re´ve´le´ une forte sous-notification
et une he´te´roge´ne´ite´ dans la nature et la disponibilite´ des
donne´es nationales sur le paludisme. L’incidence totale
ou le nombre total de cas nouveaux de paludisme
signale´s en Europe est passe´ de 6840 en 1985 a` 7244
en 1995, avec un maximum de 8438 en 1989. Les
principaux pays ayant importe´ des cas sont l’Allemagne,
la France, l’Italie et le Royaume-Uni. Dans l’ex-URSS,
l’incidence notifie´e est tombe´e de 1145 en 1989 a` 356
en 1990, apre`s cessation de l’intervention en Afgha-
nistan. Parmi les espe`ces plasmodiales importe´es, la
proportion de Plasmodium falciparum a augmente´, avec
un taux de le´talite´ allant de 0 a` 3,6% et des valeurs
toujours e´leve´es en Allemagne. Chez les voyageurs qui
s’e´taient rendus au Kenya en 1990-1995, on a note´ des
taux d’atteinte e´leve´s, qui allaient de 18 a` 207 pour
100 000.
Nos observations montrent que dans les pays
industrialise´s, le paludisme entraıˆne un taux de le´talite´
e´leve´ et constitue un proble`me de sante´ publique. Une
surveillance irre´gulie`re et le manque d’homoge´ne´ite´
dans les donne´es recueillies font obstacle a` l’e´valuation
de l’incidence, au recensement des groupes a` risque et a`
l’efficacite´ de la chimioprophylaxie.
Resumen
Paludismo importado (1985-1995): tendencias y perspectivas
El paludismo se exporta con frecuencia a zonas
industrializadas no ende´micas. Se informa aquı´ sobre
los resultados de una encuesta acerca de los casos de
paludismo notificados en los paı´ses industrializados
Table 5. Malaria attack rates in travellers to Kenya, 1990–95
1990 1991 1992 1993 1994 1995 1990–
1995
No. of Cases Rate No. of Cases Rate No. of Cases Rate No. of Cases Rate No. of Cases Rate No. of Cases Rate Average
travel- per travel- per travel- per travel- per travel- per travel- per rate
lers 105 lers 105 lers 105 lers 105 lers 105 lers 105 per 105
Austria 15 100 20 132 15 350 8 52 14 041 6 43 16 607 9 54 9 650 12 124 13 880 9 65 78
Germany 123 000 188 153 12 640 140 110 109 973 167 152 130 000 105 81 132 300 197 149 108 707 136 125 128
Italy 41 400 63 152 40 130 33 82 35 105 22 63 42 000 67 160 55 000 80 145 34 701 72 207 135
Netherlands n/aa 20 – 15 720 23 146 12 628 12 95 14 936 7 47 n/a 7 – 12 482 4 32 80
Sweden n/a 15 – n/a 5 – 22 739 4 18 27 000 7 26 30 000b 27 90 24 476 16 65 50
Switzerland 35 300 25 71 29 630 19 64 26 883 35 130 32 000 31 97 30 200 46 152 26 574 36 135 108
United Kingdom 105 100 128 122 141 420 176 124 117 458 129 110 139 000 92 66 129 000 87 67 116 106 80 69 93
USA 65 200 44 67 54 680 36 66 46 218 27 58 55 000 34 62 59 700 32 54 45 687 n/a — 61
a n/a: data not available.
b Approximate figure.
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durante el periodo 1985-1995; el objetivo era detectar
tendencias y estrategias prometedoras. Las principales
medidas de resultados analizadas fueron la incidencia,
las tasas de letalidad y las tasas de ataque entre turistas
que habı´an visitado Kenya.
Nuestra encuesta revelo´ una importante subnoti-
ficacio´n y una notable heterogeneidad en el tipo y
disponibilidad de datos nacionales sobre el paludismo.
La incidencia total o las cifras notificadas de casos de
paludismo en Europa aumentaron de 6840 en 1985 a
7244 en 1995, con un ma´ximo de 8438 en 1989. Los
principales paı´ses importadores fueron Francia, Alema-
nia, Italia y el Reino Unido. En la antigua URSS, la
incidencia notificada disminuyo´ de 1145 en 1989 a 356
en 1990, tras el cese de las actividades en el Afganista´n.
Entre las especies de para´sito del paludismo importadas,
la mayor proporcio´n correspondio´ a Plasmodium
falciparum; las tasas de letalidad se situaron entre 0%
y 3,6%, con valores sistema´ticamente altos en Alemania.
Las tasas de ataque entre los viajeros procedentes de
Kenya en 1990-1995 fueron altas, entre 18 y 207 por
100 000 viajeros.
Nuestros resultados indican que los casos de
paludismo que llegan a los paı´ses industrializados se
asocian a tasas elevadas de letalidad y siguen
representando un problema de salud pu´blica. La irregular
vigilancia y la heterogeneidad de los datos recopilados
dificultan la evaluacio´n de la incidencia, los grupos de
riesgo y la eficacia de la quimioprofilaxis.
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Tolerability of malaria chemoprophylaxis in non-immune
travellers to sub-Saharan Africa: multicentre, randomised,
double blind, four arm study
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Abstract
Objective To compare the tolerability of malaria
chemoprophylaxis regimens in non-immune
travellers.
Design Randomised, double blind, study with placebo
run-in phase.
Setting Travel clinics in Switzerland, Germany, and
Israel.
Main outcome measure Proportion of participants in
each treatment arm with subjectively moderate or
severe adverse events.
Participants 623 non-immune travellers to
sub-Saharan Africa: 153 each received either
doxycycline, mefloquine, or the fixed combination
chloroquine and proguanil, and 164 received the
fixed combination atovaquone and proguanil.
Results A high proportion of patients reported
adverse events, even in the initial placebo group. No
events were serious. The chloroquine and proguanil
arm had the highest proportion of mild to moderate
adverse events (69/153; 45%, 95% confidence interval
37% to 53%), followed by mefloquine (64/153; 42%,
34% to 50%), doxycycline (51/153; 33%, 26% to 41%),
and atovaquone and proguanil (53/164; 32%, 25% to
40%) (P = 0.048 for all). The mefloquine and
combined chloroquine and proguanil arms had the
highest proportion of more severe events (n = 19;
12%, 7% to 18% and n = 16; 11%, 6% to 15%,
respectively), whereas the combined atovaquone and
proguanil and doxycycline arms had the lowest
(n = 11; 7%, 2% to 11% and n = 9; 6%, 2% to 10%,
respectively: P = 0.137 for all). The mefloquine arm
had the highest proportion of moderate to severe
neuropsychological adverse events, particularly in
women (n = 56; 37%, 29% to 44% versus chloroquine
and proguanil, n = 46; 30%, 23% to 37%; doxycycline,
n = 36; 24%, 17% to 30%; and atovaquone and
proguanil, n = 32; 20%, 13% to 26%: P = 0.003 for all).
The highest proportion of moderate or severe skin
problems were reported in the chloroquine and
proguanil arm (n = 12; 8%, 4% to 13% versus
doxycycline, n = 5; 3%, 1% to 6%; atovaquone and
proguanil, n = 4; 2%, 0% to 5%; mefloquine, n = 2; 1%,
0% to 3%: P = 0.013).
Conclusions Combined atovaquone and proguanil
and doxycyline are well tolerated antimalarial drugs.
Broader experience with both agents is needed to
accumulate reports of rare adverse events.
Introduction
Each year an estimated 50 million travellers visit
malaria endemic areas. Around 30 000 cases of
malaria are reported annually in non-endemic,
industrialised countries, and this imported malaria
remains a public health problem with its high
mortality.1 Recommendations vary widely as to the
optimum prophylactic treatments for travellers to high
risk endemic areas, such as sub-Saharan Africa. Four
regimens are currently available: mefloquine, com-
bined atovaquone and proguanil, doxycycline, and
combined chloroquine and proguanil.2–5 The lack of
unanimity about which regimen to prescribe is mainly
due to controversy about the tolerability of antimalar-
ial drugs in non-immune, healthy travellers and a pau-
city of data from randomised controlled studies.
Two double blind studies found that tolerability to
combined atovaquone and proguanil was better than
to mefloquine or combined chloroquine and pro-
guanil.6 7 We compared the tolerability of non-immune
travellers to the four commonly recommended
antimalarial regimens.
Participants and methods
Between 1998 and 2001, we recruited people seeking
advice before travelling to malaria endemic areas.
Inclusion criteria were a consultation at least 17 days
before departure, written informed consent, age
between 18 and 70 years, and planned travel for 1-3
weeks in sub-Saharan Africa (mainly Kenya and game
parks in the Republic of South Africa). Exclusion crite-
ria were known deficiency for glucose-6-phosphate
dehydrogenase, a history of severe adverse events with
any of the four study drugs or a contraindication for
their use, pregnancy or unwillingness to adhere to reli-
able contraception, history of seizures, psychiatric
disorders, severely impaired renal or hepatic function,
concurrent or recent vaginal infections or bacterial
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unwillingness to adhere to the study protocol. Our
study was not powered to evaluate the efficacy of the
regimens for malaria prevention. No cases of malaria
were reported for any study arm.
Assignment to regimen and masking
Participants received drugs daily for 17 days before
departure, during the stay in Africa, and for four weeks
after return (see fig 1). The treatment groups were
assigned the following regimens: group 1, doxycycline
monohydrate 100 mg once daily (Vibramycin; Pfizer);
group 2, combined chloroquine diphosphate 161.21
mg (equivalent to chloroquine 100 mg base) and pro-
guanil hydrochloride 200 mg once daily (Savarine;
Zeneca); group 3, mefloquine hydrochloride 274.09
mg (equivalent to 250 mg mefloquine base; Lariam;
Roche) once weekly for 17 days before departure, dur-
ing the stay in Africa, and for four weeks after return
(placebo capsules were taken on the six days when no
active drug was required); and group 4, combined
atovaquone 250 mg and proguanil hydrochloride 100
mg (Malarone; GlaxoSmithKline) once daily for 17
days before departure, during the stay in Africa, and for
one week after return, then placebo daily for three
weeks.
A placebo run-in phase for one quarter of
participants in each arm was incorporated into the
first week of study intake. These participants then
joined one of the active treatment groups according to
randomisation.
The drugs were provided as identical capsules blis-
ter packed in weekly cards. Randomisation was
performed by the company that packed the study
drugs (Quintiles; West Lothian, Scotland). Random-
isation was from a computer generated table of
numbers in permuted blocks of five. Participants were
allocated treatment sequentially in order of study
numbers. Allocation concealment was by sealed
envelope.
Test instruments
Tolerability was assessed with three questionnaires.
Participants completed these during recruitment and
at follow up 13-11 days before departure, 6-4 days
before departure, and 7-14 days after return.
Adverse events
Adverse events were recorded using a questionnaire
similar to that used in a postal questionnaire survey of
UK travellers.8 We modified the questionnaire to
capture recognised, possible adverse events associated
with any of the four study drugs: nausea, diarrhoea,
mouth ulcers, itching, headache, strange or vivid
dreams, dizziness, anxiety, depression, visual distur-
bance, fits or seizures, abnormal reddening of the skin,
abnormal vaginal discharge or vaginal itching, and a
category for “any other.” Participants were asked to
grade the severity of the adverse events on a scale of 1
to 4: grade 1, trivial; grade 2, some interference with
daily activities; grade 3, medical advice sought; and
grade 4, hospital admission required.
Moods and feelings
Moods and feelings were captured by the profile of
mood states questionnaire.9 This questionnaire detects
tension, depression, anger, vigour, fatigue, and
confusion. Items were scored on a 5 point scale from 0
“not at all” to 4 “extremely.” The questionnaire has
been successfully used in studies on the tolerability of
malaria chemoprophylaxis in tourist and military
populations.10 11
Quality of life
Participants were asked to grade the 13 positive
statements, such as I can enjoy my everyday life, in the
quality of life questionnaire on a scale of 1 “not at all
true” to 6 “true,” The higher the score, the better the
perceived quality of life.
Statistical analyses
The main outcome measure was the proportion of
participants in each arm with subjectively moderate or
severe adverse events. The initial sample size was
intended to be 383 per arm, but because recruitment
was slower and more difficult than expected and there
was the possibility of the drugs exceeding their expiry
date, the study was closed before this sample size was
achieved.
Secondary outcome measures were the scores from
the profile of mood states and quality of life question-
naires. The 2 test was used to detect differences in the
rates and severity of self reported adverse events. We
also grouped adverse events in each arm by type
(neuropsychological, gastrointestinal, dermatological).
We performed logistic regression analyses to check for
any effect of sex or age on the incidence of adverse
events. SPSS version 6 was used for the statistical
analysis.
Analyses of variance were run on the scores for
mood states obtained for each group at each follow up.
The mean scores were converted to T scores to enable
comparison with published normal scores for college
students. To assess total mood disturbance, we summed
the scores across all six moods and weighed vigour
negatively. We checked differences in scores between
groups with repeated measures of analysis of variance,
and further analyses were checked for the effect of sex,
age, and follow up time on mood.
Quality of life scores were computed for each arm
for 13-11 days before departure to 7-14 days after
return. The mean score was used as an index score for
each arm. The score for the placebo run-in phase was
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Results
A total of 674 people (49% female) were recruited and
completed the adverse events’ questionnaire at
baseline (fig 2). After exclusion of drop-outs (changes
in travel plans, cancelled trips, decision not to take
part), our sample population comprised 623 people
who had reported any or no adverse event at baseline
or at follow up. Overall, 153 participants were assigned
to either mefloquine, doxycycline, or combined
cholorquine and proguanil, and 164 were assigned to
combined atovaquone and proguanil. Sex and age
profiles were similar in the arms. Analysis of mood was
performed on the 547 participants who completed the
mood states questionnaire at baseline and follow up.
Adverse events were analysed in 623 participants
who completed questionnaires at recruitment and at
least one of the follow up periods (table 1). Although a
high proportion of participants reported adverse
events, none were serious. At the first control time
point (13-11 days before departure) some adverse
event was reported by 34 (22%) participants in the
mefloquine arm, 36 (24%) in the chloroquine and pro-
guanil arm, 25 (16%) in the doxycycline arm, 25 (15%)
in the atovaquone and proguanil arm, and 24 (16%)
placebo users.
Twenty two participants withdrew from the study
owing to adverse events or because allocation conceal-
ment had had to be broken. Withdrawal was lowest in
the combined atovaquone and proguanil arm (n = 3;
2% (95% confidence interval, 0% to 4%), intermediate
in the doxycycline arm (n = 5; 3%, 0% to 6%) and
mefloquine arm (n = 6; 4%, 1% to 8%), and highest in
the combined chloroquine and proguanil arm (n = 8;
5%, 2% to 9%: P = 0.425). The grade of adverse event
leading to withdrawal was mild in five participants,
moderate in eight, and severe in five. No severity
grades were available for three withdrawals. No statisti-
cally significant difference was found in withdrawals
between the treatment arms (table 1).
Overall, 528 participants (85% of the sample popu-
lation) reported at least one adverse event of any sever-









Did not travel (n=4)
Consent withdrawn (n=3)
Other:
  Participated in another
   study (n=1)
  Used concomitant
   antimalarial drug (n=1)
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Did not travel (n=3)
Received study drug (n=156)
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Did not travel (n=2)
Lost to follow up (n=1)
Completed all evaluations (n=154)Completed all evaluations (n=142)Completed all evaluations (n=135)Completed all evaluations (n=138)
Did not travel (n=2)
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Used concomitant
 antimalarial drug (n=1)
Lost to follow up (n=2)
Did not travel (n=4)
Consent withdrawn (n=6)
Lost to follow up (n=3)
Did not travel (n=1)
Consent withdrawn (n=3)
Lost to follow up (n=3)
Withdrawals due to
 adverse events (n=6)
Did not complete all
 evaluations (n=5)
Stopped dosing early (n=2)
Unknown (n=2)
Withdrawals due to
 adverse events (n=8)




 adverse events (n=5)




 adverse events (n=3)
Did not complete all
 evaluations (n=5)
Stopped dosing early (n=1)
Unknown (n=1)
Fig 2 Flow of participants through trial
Table 1 Incidence of adverse events in antimalarial prophylaxis arms according to severity. Values are numbers (percentages, 95%
confidence intervals) unless stated otherwise




group (n=153) Doxycycline group (n=153)
Atovaquone and proguanil
(n=164) P value
Severity of adverse event:
Mild† 135 (88, 83 to 93) 131 (86, 80 to 91) 128 (84, 78 to 90) 134 (82, 75 to 88) 0.42
Moderate‡ 64 (42, 34 to 50) 69 (45, 37 to 53) 51 (33, 26 to 41) 53 (32, 25 to 40) 0.048
Severe§ 16 (11, 6 to 15) 19 (12, 7 to 18) 9 (6, 2 to 10) 11 (7, 2 to 11) 0.14
Withdrawals 6 (4, 1 to 8) 8 (5, 2 to 9) 5 (3, 0 to 6) 3 (2, 0 to 4) 0.42
*One participant had a transient ischaemic attack outside follow up; history of two episodes was not declared (mefloquine serum concentrations were negligible).
†Trivial but some discomfort noted.
‡Interferes with daily activity.
§Medical advice required.
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events (primary end point). The highest incidence was
in the combined chloroquine and proguanil arm and
the lowest in the combined atovaquone and proguanil
arm (n = 69; 45%, 37% to 53% and n = 53; 32%, 25% to
40%, respectively). Fifty five participants (9%) reported
at least one severe adverse event. The highest incidence
was in the combined chloroquine and proguanil arm
and the lowest in the doxycycline arm (n = 19; 12%, 7%
to 18% and n = 9; 6%, 2% to 10%) (table 1).
The mefloquine arm had the highest incidence of
moderate to severe neuropsychological events (n = 56;
37%, 29% to 44%: P = 0.003, table 2) and the lowest
incidence of moderate to severe skin events (n = 2; 1%,
0% to 3%: P = 0.013). The combined chloroquine and
proguanil arm had the highest incidence of moderate
to severe skin adverse events (n = 12; 8%, 4% to 12%).
Women reported significantly more neuropsychologi-
cal, gastrointestinal, and skin problems than men. Men
in the combined chloroquine and proguanil arm were
more likely to have moderate skin problems.Women in
the mefloquine arm were significantly more likely to
have moderate neuropsychological problems than
women in the doxycycline or combined atovaquone
and proguanil.
No significant differences in mood were found
between the treatment arms. Scores were in the normal
range, and means deviated by no more than one
standard deviation. All arms showed good mean index
scores for quality of life: combined atovaquone and
proguanil 4.9 (4.8 to 5.1); combined cholorquine and
proguanil 4.9 (4.6 to 5.0); doxycycline 4.8 (4.7 to 5.0);
and mefloquine 4.8 (4.7 to 4.9: P = 0.41 for all). The
mean index for the placebo group was 4.9.
Discussion
Tolerability to the four currently recommended
antimalarial drugs, mefloquine, doxycycline, combined
chloroquine and proguanil, and combined atovaquone
and proguanil, is high, with no serious adverse events
and good quality of life reported. Moods and feelings
were also good, with high scores for “vigour” and low
scores for “tension,” “depression,” “anger,” “fatigue,”
and “confusion”—the so-called iceberg profile.
Although several factors influence the choice of
antimalarial regimen, tolerability is important to
encourage compliance to treatment of non-immune
travellers to endemic areas. A recent evaluation of
circumsporozoite seroconversion studies showed
that a high proportion of travellers to West Africa,
East Africa, and South Africa will be exposed to
Plasmodium falciparum.12
Our study is the first to concomitantly examine the
tolerability of the currently recommended antimalarial
regimens in a uniform group of non-immune tourists.
Over three quarters of our participants reported inter-
current events. Even in the initial placebo group, where
travel was a not a confounding feature, the incidence of
adverse events was comparable to the active treatment
groups.
Relation to other studies
More that 3000 people have been enrolled in five
placebo controlled trials comparing combined
atovaquone and proguanil with either combined chlo-
roquine and proguanil, mefloquine, doxycycline, or
placebo alone. Our study agreed with the favourable
safety profile for atovaquone and proguanil shown in
comparator studies.6 7–13 Data on long term tolerability
and post marketing surveillance are now required.
Previous studies of doxycycline have been limited
to predominantly male soldiers in whom the drug was
well tolerated.14–21 Oesophageal ulceration associated
with doxycycline prophylaxis was a common reason
for admission to hospital of US troops deployed in
Somalia.22 This was not a problem in our study,
Table 2 Proportion of participants in each antimalarial prophylaxis arm reporting adverse events, by type and severity, Values are
numbers (percentages, 95% confidence intervals) unless stated otherwise
Type of adverse event Mefloquine group (n=153)
Chloroquine and proguanil
group (n=153) Doxycycline group (n=153)
Atovaquone and proguanil
group (n=164) P value
Neuropsychological*:
Severe 8 (5, 2 to 9) 6 (4, 1 to 7) 1 (1, 0 to 2) 5 (3, 0 to 6) 0.139
Moderate 56 (37, 29 to 44) 46 (30, 23 to 37) 36 (24, 17 to 30) 32 (20, 13 to 26) 0.003
All events 118 (77, 70 to 84) 107 (70, 63 to 77) 105 (69, 61 to 76) 109 (67, 60 to 74) 0.187
Gastrointestinal†:
Severe 6 (4, 1 to 7) 9 (6, 2 to 10) 3 (2, 0 to 4) 5 (3, 0 to 6) 0.312
Moderate 24 (16, 10 to 22) 31 (20, 14 to 27) 14 (9, 5 to 14) 26 (16, 10 to 22) 0.058
All events 89 (58, 50 to 66) 93 (61, 53 to 69) 81 (53, 45 to 61) 88 (54, 46 to 61) 0.451
Skin‡:
Severe 1 (1, 0 to 2) 2 (1, 0 to 3) 3 (2, 0 to 4) 1 (1, 0 to 2) 0.635
Moderate 2 (1, 0 to 3) 12 (8, 4 to 12) 5 (3, 1 to 6) 4 (2, 0 to 5) 0.013
All events 36 (24, 17 to 30) 40 (26, 19 to 33) 36 (24, 17 to 30) 34 (21, 15 to 27) 0.730
Skin and vaginal§:
Severe 2 (1, 0 to 3) 2 (1, 0 to 3) 4 (3, 0 to 5) 1 (1, 0 to 2) 0.509
Moderate 5 (3, 1 to 6) 13 (9, 4 to 13) 9 (6, 2 to 10) 4 (2, 0 to 5) 0.058
All events 45 (29, 22 to 37) 45 (29, 22 to 37) 42 (28, 20 to 35) 40 (24, 18 to 31) 0.717
Other:
Severe 3 (2, 0 to 4) 5 (3, 0 to 6) 4 (3, 0 to 5) 2 (1, 0 to 3) 0.644
Moderate 12 (8, 4 to 12) 16 (11, 6 to 15) 12 (8, 4 to 12) 12 (7, 3 to 11) 0.748
All events 46 (30, 23 to 37) 47 (31, 23 to 38) 48 (31, 24 to 39) 36 (22, 16 to 28) 0.201
*Symptoms include headache, strange or vivid dreams, dizziness, anxiety, depression, sleeplessness, and visual disturbance.
†Nausea, diarrhoea, mouth ulcers.
‡Itching, abnormal reddening of skin.
§Itching, abnormal discharge.
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possibly because we used the monohydrate salt of
doxycycline and because participants were instructed
to take drugs with a glass of water after food and not
before bedtime. Skin reactions, including photosensi-
tivity, were expected. One third of the severe problems
with doxycycline were skin reactions, although the
highest proportions of all such reactions were in the
combined chloroquine and proguanil arm. Our
participants were advised to use sunscreens and were
warned that one of the study drugs was potentially
phototoxic. Regression analysis showed no increased
risk of vaginal candidiasis with doxycycline. This good
tolerability confirms the results of an uncontrolled,
questionnaire survey of Australian travellers.23
A recent meta-analysis evaluated the tolerability of
mefloquine in 2750 non-immune adults and found
that the incidence of adverse events was no greater
than that of any comparator regimen.24 Tolerability
studies have, however, repeatedly highlighted the
problem of neuropsychological problems with meflo-
quine. Several studies and a review have shown that
women are significantly more likely to experience
adverse events with mefloquine than with comparator
drugs.8 10 23 25 We found a significant excess of moderate
neuropsychological problems with mefloquine com-
pared with doxycycline and combined atovaquone and
proguanil but not with combined chloroquine and
proguanil. Furthermore, regression analysis between
the medication and sex showed that significantly more
women taking mefloquine reported mild to moderate
neuropsychological problems (including headache
and sleep disturbances) than those taking the other
drugs. This confirms the results of earlier uncontrolled
questionnaire studies.
Although studies have shown that combined
chloroquine and proguanil is associated with a high
incidence of adverse events, some health authorities
still recommend its use.7 8 26 We found the poorest
tolerability to this combination, but the drug remains
an alternative treatment when other drugs are
contraindicated.
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Summary This longitudinal study of travellers to Africa taking mefloquine ( M Q )  chemoprophylaxis 
aimed to  quantify and assess non-serious adverse events (AE) occurring during short-term 
prophylaxis and relate these to concentrations of racemic MQ, its enantiomers and 
metabolite. A total of 420 volunteers ( 5 2 %  F) participated. AEs with some impact on 
activities were reported by I I .2% of participants including 7.9 % of neurological/psychiatric 
symptoms. Women were more likely to report AEs (P=0.02). The standardized 
questionnaires used showed more pathological indicators in travellers who reported 
subjective AE with significantly more dizziness, distress, sleep disturbances and a high total 
mood disturbance (TMD) in the AE group. There was, however, no significant performance 
deficit in computerized psychomotor tests in those experiencing AE. Furthermore, no 
significant differences were observed in enantiomer ratios, metabolite concentrations, or 
racemic M Q  levels in participants with or without AEs suggesting that these factors are not 
the main predictors of mefloquine intolerability. 
keywords mefloquine, adverse event 
correspondence Dr Patricia Schlagenhauf, Institute of Social and Preventive Medicine, 
University of Zurich, Sumatrastr. 30, CH-8006, Zurich 
Introduction 
of two erythro enantiomers (RS and SR)  (Basco 
et a/. 1992). A recent study demonstrated that M Q  
Mefloquine (MQ) is currently the chemoprophylactic 
agent of choice for travellers to areas where chloro- 
quine resistant P. falciparum is highly endemic 
(WHO 1995; Raeber et al. 1992; CDC 1994; 
Bradley 1993). Mefloquine is a 4-quinolinemethanol 
available commercially as the racemic 50:jo mixture 
pharmacokinetics are highly stereo-selective with a 
significantly longer mean terminal half-life for the SR 
enantiomer (430 hours) compared to the RS (172 
hours). During 250 mg weekly chemoprophylaxis the 
mean steady-state SR concentration in plasma was 
6.6 times higher than that of the RS (Gimenez et al. 
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1994). Furthermore, the SR enantiomer is a more 
potent acetylcholinesterase inhibitor (Ngiam & Go 
1987). Mefloquine use has been associated with a 
wide spectrum of neuropsychiatric adverse events 
(Sturchler et al. 1990; Weinke et al. 1991; Bem 
et al. 1992) and it has been speculated that the 
enantiomers or, indeed, the carboxylic acid metabo- 
lite ( M M Q )  may play a role in mefloquine related 
adverse events (Hakansson et al. 1990). The objec- 
tives of this study were ( i )  to study the pattern of 
adverse events in relation to the concentrations of 
MQ enantiomers and the main metabolite; (ii) to 
assess the impact of non-serious adverse events and 
whether or not they can be assessed objectively with 
standardized questionnaires and computer tests; and 
(iii) to estimate compliance with the prophylactic 
regimen. 
Subjects and methods 
Travellers to tropical Africa were invited to enter the 
study when they visited the Vaccination Centre a t  
Zurich University during the period November 1992 
to January 1994. The study was approved by the 
Ethical Committee and its conduct conformed with 
the Declaration of Helsinki (as amended in Tokyo 
and Venice). Exclusion criteria included age <18 or 
>65 years, history of seizure disorder, past history 
of psychosis or severe depression, known allergy or 
sensitivity to M Q  or related compounds, concurrent 
use of cardioactive medication, compromised renal. 
or hepatic function, pregnancy, or the intention to 
become pregnant within 3 months of mefloquine use. 
The nature of the study was explained to the 
volunteers and they received no financial benefit but 
were provided with MQ free of charge. Each subject 
signed a written informed consent and received the 
exact amount of medication required for their stay 
in Africa plus a simple schedule showing the dates 
for tablet taking and interviews at  the vaccination 
centre. The volunteers followed a slightly modified 
schedule of chemoprophylaxis in that they took one 
tablet of mefloquine 250 mg weekly for z weeks 
prior to departure (instead of one week as currently 
recommended); otherwise, the regimen was exactly 
in accordance with recognized guidelines ( W H O  
1995) for the duration of the trip and for 4 weeks 
after return from tropical Africa. MQ was to be 
administered after the main meal with a glass of 
water on the same day each week. The participants 
visited the Vaccination Centre twice more; once 
prior to travel (after the first or second tablet) and 
once after return from Africa (during the first or 
second week after return). Both adverse events and 
compliance were assessed at  these interviews. 
During both visits blood was collected in glass 
heparinized vacutainer tubes (Becton Dickinson) by 
venepuncture. The separated plasma samples were 
analysed for concentrations of racemic mefloquine 
and its carboxylic acid metabolite 2,8-bis- 
(trifluoromethyl)-4-quinoline carboxylic acid (MMQ) 
using a high performance liquid chromatography 
(HPLC) method (Bergqvist et al. 1988). The limit of 
determination was 0.25 ymol/l for both M Q  and 
MMQ. Thereafter the ratio between the two 
enantiomers RS and SR was determined using an 
enantio-selective HPLC method (Wallen et al. 1994). 
Finally, the concentration of each enantiomer was 
calculated by multiplying the ratio with the total 
M Q  concentration. The limit of determination for 
each enantiomer was approximately 0.1 ymol/l. Due 
to the variability of the sampling times in relation to 
mefloquine intake, SR:RS ratios were used rather 
than absolute concentrations in assessing the possible 
influence of the enantiomers. 
Adverse events (AEs) were not prompted but were 
reported at  the interviews in response to the ques- 
tion, ‘How d o  you feel since you took the last 
tablet?’ AEs reported at  the interviews were con- 
sidered neuropsychiatric in nature if  they reflected 
sleep disturbances, dizzinesshertigo, headache, mood 
changes, unusual or vivid dreams, decreased concen- 
tration or phobias. Only adverse events with some 
impact on activities were included in the study. Vari- 
ous standardized tests were used to evaluate these 
AEs: the Neurobehavioral Evaluation System (NES) 
is a series of computerized tests designed to provide 
quantitative neurobehavioural outcomes (Baker et al. 
1985; Letz 1991). A series of 4 tests (including sub- 
tests) were used in this study: symbol digit substitu- 
tion, hand/eye coordination, visual digit span and 
the switching attention test. Participants reporting 
neuropsychiatric type AE and control persons 
(matched for sex, approximate age and dosing 
schedule) performed this battery of tests after an 
initial familiarization run. 
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Approximately 3 months after the last M Q  dose 
candidates from the AE group performed a rerun of 
the test battery providing the follow-up data. Scores 
were compared between M Q  users with AE and the 
control group and also between the AE test and 
follow-up results. The control group was not 
reassessed. 
In addition to the NES battery, each test session 
required the completion of two standardized ques- 
tionnaires; the Environmental Symptoms Question- 
naire (ESQ) contains 68 questions related to all body 
systems (Sampson & Kobrick 1980; Sampson et al. 
1994). The candidate marks a box from one of 6 
graded answers ranging from ‘not at all’ to 
‘extreme’. The second questionnaire, the Profile of 
Mood States (POMS), contains 65 questions and is 
designed to detect 6 categories of feelings: tension, 
vigour, fatigue, anger, depression and confusion. The 
POMS answers are graded with a 5-point score 
ranging from ‘not at all’ to ‘extremely’ (McNair & 
Droppelman 1981; Johnson et al. 1989). The raw 
scores for each mood were also converted to 
T-scores and these were compared to the T-scores of 
a reference group (college age American adults 
where for each mood the mean is 5 0  and the 
standard deviation 10 (McNair & Dropelman 
1981)). Those with adverse events also completed 
follow-up questionnaires approximately 3 months 
after taking the last mefloquine dose. Intensity scores 
were compared between the 3 data sets (matched 
controls, AE group test and follow-up scores). 
Compliance was also assessed at the interviews. 
For the purposes of the study full compliance was 
defined as taking the correct amount of medication 
(one tablet) on the specified day each week for the 
predetermined duration of chemoprophylaxis as 
shown on each individual schedule (tailor-made for 
each traveller). Poor compliance was defined as 
erratic use of the medication, i.e. the tablets adminis- 
tered weekly, albeit irregularly and on various week 
days. Those who missed doses, who overdosed or 
who prematurely discontinued their regimen were 
considered non-compliant. 
Data analysis 
The Statistics Package for the Social Sciences (SPSS) 
was used to analyse demographics, NES scores and 
compliance. For NES scores, significance was 
determined using the t-test for independent samples 
(AE group and controls) and the Wilcoxon 
matched-pairs signed rank test for AE test and 
follow-up pairs. Plasma levels were analysed using 
StatView software and the non-parametric Mann- 
Whitney U-test was used to compare SRIRS ratios, 
M Q  and MMQ levels in groups with and without 
adverse events. POMS and ESQ scores were 
analysed using STATISTICA. The incidence of ESQ 
symptoms according to group was assessed by xz. 
For the POMS scores, one-way analyses of variance 
(with Tukey unequal N post hoc comparisons 
when appropriate) on the three groups were 
performed. 
Results 
A total of 420 volunteers (52% female) were 
recruited for the study. Most participants (46%) 
travelled to Kenya and the durations of their visits 
were 2-4 weeks (82 .1%).  The subjects’ ages were 
widely distributed with 41% in the 18-29 year 
group and 22.9% in the 30-39 year group. For the 
evaluation of adverse events, 26 persons were 
excluded (due to changes in travel plans and missed 
appointments). Among the 394 evaluated volunteers, 
44 (II.z%) reported one or more adverse events 
with impact on activity (Figure I )  and 31 (7.9% of 
total or 70.4% of the AE group) had one or more 
neuropsychiatric symptoms. One event, alkalosis, 
was serious, requiring hospitalization. This AE was 
considered a result of a prolonged tropical sojourn 
and unrelated to mefloquine use. Almost twice as 
many women as men reported subjective AEs 
(P=o.o2). 
Influence of enantiomers 
There was no significant difference in SR:RS ratios 
for those with or without AEs at the first and 
second visit (P=0.67 and P=0.82 respectively) and 
the same held true for those reporting neuro- 
psychiatric symptoms (P=0.69). The median SR:RS 
ratio at visit I was 2.87 and this increased to 4.94 at 
the second visit, showing a large overall increase in 
the relative proportional concentration of the SR 
enantiomer. 
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Figure I Onset of adverse events 
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Influence of the carboxylic acid metabolite (MMQ) 
The median concentration of M M Q  at  the initial 
visit was 1.93 pmoV1 in those who reported no AEs 
and 1.89 pmol/l in those reporting an adverse event 
(P=0.996).  Similarly, a t  the second visit, the median 
concentration of MMQ in those without AEs was 
7.07 us 8.27 pmol/l in those with AEs (P=o.r86). 
Influence of racemic mefloquine concentrations 
At visit I, when most of the AEs were reported, the 
median concentration of MQ in participants with 
AEs was 1.15 vs 0.98 pmol/l in those without AEs 
(P=0.18). At the second visit the M Q  median con- 
centrations were 2.20 and 2.55 pmol/l for those with 
and without AEs respectively (P=0.17). 
NES results 
There were no significant differences in NES scores 
in any test or test subunit between those with AEs 
and the control group (Table I). Those with adverse 
events who could be reassessed showed no signifi- 
cant differences between test and follow-up scores 
(P range 0.47-1) (Table 2 ) .  
ESQ results 
The results of the analyses were consistent in show- 
ing that the adverse event group reported signifi- 
cantly more intense feelings of dizziness, distress and 
sleep disturbance than the subjects in the control 
group or the AE subjects a t  follow-up assessment 
(P<0.05). Conversely, no significant differences in 
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Table I NES scores for AE group 
and matched controls AE group Controls P 
Test type (NES battery) (n=19) ( n = 2 4 )  R e s t  (independj 
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symptoms’ incidence were found between the control 
and follow-up groups. With regard to individual 
symptoms, the adverse event group reported the 
presence of light-headedness (P=o.oo j), dizziness 
(P=o.oI), restlessness (P=o.ooq), difficulty sleeping 
(P=o.ooz) more often than did the control and 
follow-up groups. Three exceptions were ‘sore throat’ 
which was not reported in the control group and the 
items ‘alert’ and ‘feeling good’ which were both re- 
ported more frequently in the control and follow-up 
groups. A rank ordering of ESQ symptoms according 
to mean intensity level indicated that positive symp- 
toms (feeling good, alert, wide awake and hungry) 
were characteristic of the control and the follow-up 
groups. Negative symptoms (having difficulty sleep- 
ing, feeling tired, having poor concentration etc.) were 
characteristic of the adverse event group. 
POMS results 
The results were consistent in showing that those 
subjects with adverse events reported significantly 
more intense moods of tension, depression, fatigue 
and confusion than the subjects of either the control 
or follow-up groups. No differences were found 
between the scores of the control and the scores of 
the AE group at follow-up. The mood ‘vigour’ was 
lowest in the AE group (Table 3a and b). Graphic 
representation of the POMS T-scores shows that the 
predominant mood for the control and baseline 
groups is the positive mood vigour, which is the 
mood pattern typical of the physically active adult. 
Vigour was found to be least intense for subjects in 
the adverse event group (Figure 2 ) .  We also analysed 
for differences between the 3 groups with respect to 
the global index, ‘total mood disturbance’ (TMD), 
which is calculated by summing the raw scores 
across all six moods (tension, depression, anger, 
vigour, fatigue, confusion) and weighting vigour 
negatively. TMD was highest in the adverse event * 
group (Table 3 b). 
Compliance assessment 
Seven persons who failed to keep any appointment 
were excluded from the compliance assessment. 
Thus, 413 volunteers were available for complete 
compliance assessment. At the interviews each 
subject was questioned carefully, but in a non- 
threatening way, regarding compliance with the 
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Table 2 Comparison of test and 
follow-up NES scores in the AE 
group 
AE group 
AE group at follow-up Wilcoxon 
Test type (NES battery) test scores (n=11) matched P 
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chemoprophylactic regimen. In 26 (6.3 %) persons, 
the compliance could not be verified as these partici- 
pants did not attend the second visit due to time 
constraints. Most of the volunteers (n=351, 85%) 
claimed to be fully compliant with the regimen and 
found a once weekly regimen easy to comply with. 
Some 16 (3.9%) subjects described poor compliance 
taking the tablets weekly but on the wrong day or a 
few days later than scheduled. Some 20 persons 
(4.8%) described non-compliance: 8 due to perceived 
adverse events, one due to unplanned pregnancy, in 
one case the medication was stolen, 3 persons were 
non-compliant due to a change in travel plans, 4 
individuals over-used the medication, and 3 prema- 
turely interrupted the chemoprophylaxis due to peer 
pressure or ambivalence. Women tended to be more 
compliant than men but age was the only significant 
determinant of compliance (P<o.os) (Table 4). Of 
those who over-used the medication, two used 
additional mefloquine doses as a therapy for sus- 
pected malaria (one in a presumptive setting, the 
other o n  medical advice); retrospective serological 
tests to confirm the diagnosis were negative. Another 
over-user administered one tablet daily for 3 days 
prior to travel despite having received a schedule 
with specified tablet taking dates. 
Discussion 
Adverse event assessment 
In general, mefloquine was well tolerated. The 
adverse events were spontaneously reported at the 
interviews and not prompted. The incidence of AE 
( I  1.2%) is lower than previously reported when 
travellers were surveyed by questionnaire only 
(18.8%) where a prompt list of adverse events is 
available (Steffen et al. 1993). Sleep disturbances, 
including dreams, mood changes, nervousness, 
headache, and decreased concentration, the so- 
called neuropsychiatric events, tended to occur early 
in chemoprophylaxis (Figure I )  after intake of the 
first or second dose and often resolved spon- 
taneously. This pattern has been previously observed 
by Lobel et al. (1993) and Boudreau et al. (1993). 
Causality was not assessed and it can be postulated 
that psychological pre-travel stress and the physio- 
logical demands of travel to  tropical Africa may be 
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Table 3 a, Intensity scores and b, summary of POMS results 
Parameter 















Adverse events ( n = z ~ )  Follow-up (n=13) 
















AE group ( 2 5 ) /  
follow-up (13)  
51 
48 





AE group (25)I 
controls (23 )  
8.0 5.6 43 
3.4 4.5 4 0  
6.1 5.8 45 
16.7 5.8 52  
5 . 2  4.9 42 
4.5 4.0 3 8  
Highest In AE group 0.011 0.053 0.04 3 
Highest in AE group 0.013 0.067 0.043 
Highest in AE group 0.000 0.007 0.000 
Highest in AE group 0.000 0.005 0.001 
n.s. n.s. 
Lowest In AE group 0.009 0.036 0.066 
Highest in AE group 0.012 0.034 0.107 
Controls (n=23) 
Mean s.d. T' 
9.3 5.9 44 
5.0 8.3 4 2  
4.7 4.4 43 
5.0 6.2 41  
14.3 7.7 48 
6.5 4.3 41  
' The T-scores are standard scores with American adults (college-age) as the reference group; the mean is 5 0  and the 
standard deviation for a T-score is always 10 
6o r 
351 1 I 1 I I 
Tension Anger Fatigue 
Figure 2 Profile of Mood States (POMS) scores for AE 
and control groups 0 ,  AE group (n=25); 0, AE group a t  
follow-up (n=13) ;  V, control group (n=23).  
Depression Vigour Confusion 
responsible for some of these events. Furthermore, 
many of the reported symptoms may be considered 
part of normal life events during a 7-12 week 
period. For obvious reasons, a control group without 
medication would have been unethical. N o  serious 
neuropsychiatric adverse event was reported in this 
study and such events are rare during administration 
of mefloquine for chemoprophylaxis. The incidence 
of serious events has been estimated at  1/10 600 and 
1/13 ooo by Steffen et al. (1993) and Weinke et al. 
(199 I )  respectively. 
The most commonly reported events were sleep 
disturbances (usually insomnia) and dizziness. The 
ESQ scores further reinforced this AE profile with 
significantly more reports of the symptoms (light- 
headedness, dizziness, restlessness and sleeping diffi- 
culty) in the AE group. Negative symptoms were 
characteristic of the AE group during M Q  intake 
but not a t  follow-up, suggesting that this negative 
global effect in some individuals may be associated 
with MQ administration and disappears after dis- 
continuation of the drug. The POMS results further 
illustrate the type of moodiness and lack of vigour 
in the AE group. Feelings of depression and neuro- 
psychiatric adverse events have been associated with 
mefloquine use (Weinke et al. 1991; Bem et al. 
1992). Those with AEs who also completed the 
follow-up questionnaires showed a return of vigour 
and well-being after discontinuing mefloquine use. It 
should be noted, however, that the POMS and ESQ 
scores do not indicate clinical significance in terms of 
pathology. The POMS assesses transient moods and 
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Table 4 Compliance according to 
Age group n Male compliance (YO) Female compliance (%) sex and age 
(18-29) 159 87.8 89.4 
(30-39)  9 2  80 86.5 
(40-49) 74 97.4 TOO 
’ 5 0  60 96.3 I00 
P = 0 . 0 5 3  P=o.o17 
OveralI table P=o.oor 
the purpose of the ESQ is to increase the sensitivity 
of research so that mild symptoms are captured, 
especially complaints which d o  not require formal 
medical attention but which nonetheless are likely to  
affect those using chemoprophylaxis. These neuro- 
psychiatric effects and feelings undoubtedly occur in 
out AEs. It is possible that the sometimes prolonged 
interval between adverse event occurrence and plasma 
sampling may have had an impact. 
Compliance 
a subgroup of mefloquine users but the importance 
of such events is unclear. This study tried to assess 
the impact of these non-serious AEs using the NES 
test which has been used to detect performance 
changes in other studies (Fidler et al. 1987; Baker 
et al. 1988; Rubin et al. 1991). We found no signifi- 
cant decline in test performance in users with AEs 
compared to controls, suggesting that although these 
adverse events occur, their impact is minimal and 
that the individuals suffer no detectable decline in 
neurological function, an important issue when one 
considers how many M Q  users drive cars and other- 
wise continue their normal daily routines. Those per- 
sons who performed the test on two occasions, with 
AEs and again at  a follow-up session, showed no 
significant improvement in scores a t  the later session. 
Boudreau et al. (1993) have also found no compro- 
mise in function due to  dizziness or incoordination 
in mefloquine users. 
Adverse events in relation to  concentrations of 
enantiomers and metabolite 
An analysis of the plasma concentrations and ratios of 
the S k R S  enantiomers showed no significant differ- 
ences in participants with or without adverse events, 
suggesting that the potential for adverse events is not 
due to relative changes in enantiomer or metabolite 
concentrations. Neither the plasma concentrations of 
M M Q  nor total M Q  levels showed any significant dif- 
ferences in mean concentrations in users with or with- 
The issue of travellers’ compliance with antimalarial 
regimens needs clarification and there are few 
reliable data on compliance with chemoprophylactic 
drugs. Based on travellers’ self-assessment, Steffen 
and Schlagenhauf (1993) reported that travellers 
while abroad were less compliant with a two-drug 
daily regimen of chloroquine plus proguanil (78.4%) 
than with the one-drug weekly regimen of meflo- 
quine ( 9 ~ 5 % ) ~  with a decrease in compliance on 
return. This study sought to estimate compliance 
based on interview assessment. Variables such as 
duration of stay, age, sex and occurrence of side- 
effects have been shown to influence the quality of 
compliance (Lobe1 et al. 1990; Phillips-Howard et al. 
1990). We found that the age group 18-29 years 
was significantly more compliant than the group 
aged 3 0-3 9 years; otherwise, compliance increased 
with age. The complexity of the prescription 
(number of tablets, frequency of intake, duration) is 
a major determinant of non-compliance (Haynes & 
Sackett, 1976) and travellers are most likely to com- 
ply with a simple, once-weekly, chemoprophylactic 
regimen. Our study reflects this hypothesis showing 
a high degree of patient compliance (85%).  The 
degree of compliance in this study is considerably 
greater than that previously reported by some other 
investigators (von Kessel & Lilijveld 1992; Code et 
al. 1989)  and may actually be induced by the type of 
volunteer who participated in the study. Due to the 
rather intensive nature of study participation there 
may be a bias for the inclusion of subjects who are 
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temperamentally more likely to  comply with 
instructions. It is also probable that the provision of 
a personal tablet taking timetable and the discipline 
of study participation contributed to  the favourable 
compliance result. This positive effect has been 
shown previously (Mazzulo & Lasagna 1972). 
Conclusions 
We conclude that M Q  is usually well tolerated in 
short-term chemoprophylaxis but AEs with impact 
on activity are reported by 11.2% of participants. 
Women were significantly more likely to report AEs. 
The majority of these AEs (70.4%. or 7.9% of 
users) are of the minor neuropsychiatric type and 
tend to be mild and transitory in nature with no sig- 
nificant incapacitation or performance deterioration 
in NES computer tests. The disposition of meflo- 
quine is highly stereo-selective but neither the 
concentrations of the separate enantiomers, nor 
total MQ, nor M M Q  appear to be related to the 
occurrence of mild AEs. 
Some of the AEs reported during mefloquine use 
could be attributed to travel stress or routinely 
occurring symptoms. Adverse events tended to occur 
early during the chemoprophylaxis. For certain 
travellers it may be advantageous to have a 
running-in period of z weeks before departure so 
that any AE occurring can be monitored in the home 
country. This would also ensure higher protective 
plasma M Q  levels when entering the endemic area. 
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Abstract. Due to presumed adverse performance impact, a World Health Organization clause currently restricts
the use of mefloquine malaria chemoprophylaxis in individuals requiring fine coordination and spatial discrimination.
We conducted a double-blind, placebo-controlled, cross-over study to quantitatively assess the effects of mefloquine
at steady state on performance in 23 trainee airline pilots. Flying performance was assessed using a flight simulator,
psychomotor function was evaluated, sleep and wake cycles were monitored, and symptoms and moods were assessed
using standardized questionnaires. A simplified postural sway meter recorded sway in three test positions. In the
mefloquine loading dose phase, there. was one withdrawal due to dizziness, diarrhea, and flu-like symptoms, and three
volunteers reported nonserious, sleep-related adverse events. There was no significant difference in flying performance,
psychomotor functions, or mean sway for any test position. Nonsignificant reductions in mean total nocturnal sleep
(mefloquine 450 mm versus placebo = 484 mm) and poorer sleep quality were detected in the mefloquine phases.
The mood findings indicated a predominance of positive states, with vigor the predominant mood in all phases. No
significant performance deficit was documented under laboratory conditions during use of mefloquine at steady state.
Tolerability of prophylactic antimalarial drugs is an issue
of increasing importance and complexity. Mefloquine is cur
rently the prophylactic drug of choice for travelers at high
risk of exposure to chloroquine-resistant falciparum ari'
This agent has been associated with the occurrence of neu
rologic and psychiatric events that have been reported after
both prophylactic and therapeutic use.2@ Minor neurologic
events are frequent and include dizziness, vertigo, headache,
sleep, visual and auditory disturbances. Serious adverse
events (AEs) such as seizures, disorientation, and toxic en
cephalopathy have also been reported (World Health Orga
nization, 1991, unpublished data),2 usually after therapeutic
doses and in patients with a predisposing medical history.
Against this background, the World Health Organization
cautions that â€œpersonsinvolved in tasks demanding fine co
ordination and spatial discrimination (e.g., air crews) should
not use mefloquine for prophylaxis and they should avoid
such tasks for at least two weeks following therapeutic
useâ€•.â€T˜his clause has many ramifications, not just for fre
quenfly exposed groups such as pilots and military personnel
involved in fine precision work, but it has also been inter
preted by some to apply to the nonimmune traveler who
wishes to drive a car, to dive, or to operate any machinery
while taking mefloquine chemoprophylaxis. It is very diffi
cult to prove safety once someone or some group suggests
that AEs are associated with the drug. Despite this seemingly
insurmountable obstacle, we believed that it was imperative
to provide objective data on the performance impact of me
floquine, especially since recent investigations have shown
that although minor neuropsychiatric events occur during
prophylaxis with many antimalarials (including mefloquine),
these events have minimal impact on performance.5 With
regard to the incidence of minor neurologic symptoms (such
as dizziness) that occur during the use of some antimalarials,
several studies of mefloquine chemoprophylaxis in nonim
mune persons have shown comparable tolerability to other
agents such as ch!oroquine and doxycycine.@ In fact, San
chez and others found that lightheadedness was reported
more frequently in doxycycline users than in a group taking
mefloquine (19.2% versus 10.5%).@ Furthermore, a Swedish
group explored the effects of mefloquine using subspeciali
zed techniques such as posturography, nystagmus recording,
and Bekesy audiometry in 10 healthy adult volunteers and
found no significant AEs on the vestibular â€˜Â°
Clinical data have not supported the hypothesis that the
use of prophylactic mefloquine interferes with a pilots' abil
ity to carry out his or her tasks. The main objective of this
study was to quantitatively assess the impact of prophylactic
mefloquine, at steady state levels, on pilots' performance.
Secondary objectives were to objectively study the effects
of loading dose and weekly mefloquine on sleep using ac
tigraphy (electronic accelerometerâ€”based physical activity
monitoring using wrist-worn devices) and finally to assess
the general impact of mefloquine using a battery of objec
tive, quantitative tests.
MATERIALS AND METHODS
Experimental design and population. This double-blind,
randomized, cross-over study of mefloquine versus placebo
was conducted with trainee pilots attending the Swiss Civil
Aviation School during the classroom phases of their study
in 1993â€”1994. There were a total of 22 men and one woman
with a mean age of 27 years, a mean weight of 77 kg, and
a mean height of 182 cm. The study was approved by the
Ethics Committee of the University of Zurich and each par
ticipant signed an informed consent form on enrollment.
Exclusion criteria. These included history of a seizure
disorder; psychosis or severe depression; known allergy or
sensitivity to mefloquine or related compounds; concurrent
use of cardioactive medication; compromised renal or he
patic function; pregnancy or the intention to become preg
nant within three months of mefloquine use; use of meflo
quine in the preceding two months, and use of hypnotics or
tranquilizers during the two weeks prior to testing and al
cohol within 12 hr of testing.
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Medication. To achieve steady state conditions in a lim
ited time frame, medication (mefloquine 250 mg, LariamÂ®;
F Hoffmann-La Roche, Base!,Switzerland)was admims
tered more rapidly than usual as a loading dose phase5 with
one tablet given daily on three consecutive days followed
from day 8 by once a week administration of one tablet for
three consecutive weeks. The placebo was administered with
the same frequency. Each participant was tested intensively
one day after administration of the final (sixth) tablet. Blood
samples were also obtained on testing day to assess drug!
blood profiles. Plasma samples were later analyzed for total
concentrations of mefloquine and its carboxylic acid metab
olite using a high-performance liquid chromatography meth
od as described by Bergqvist and others.â€• Due to the long
elimination half-life (mean = 18 days) of mefloquine, there
were protracted intervals of four to six months between the
cross-over study phases in which subjects receiving placebo
in the first testing period received mefloquine during the sec
ond testing period.
Symptom assessment. Throughout dosing, the partici
pants were monitored and questioned regarding their general
well-being. The participants were seen 1) prior to taking any
medication, 2) at the end of the first week (during which the
loading dose was administered, 3) one week before testing,
and 4) on the testing day itself when they were asked to
report any changes from normal and questioned with regard
to any symptoms experienced while taking the drug.
Testing methodology. One day following the final mcd
ication dose, the participants were intensively tested using
the Instrument Coordination Analyzer (ICA).'2 The ICA is
used in the selection of trainee pilots and is a complex in
strument that measures multiple task ability as objective val
ues. It simulates simplified cockpit tasks with controls for
the altitude, direction, and speed. The ICA measures coor
dination, psychomotor function, spatial discrimination, fine
coordination, and stress resistance. The participant was re
quired to simultaneously conduct two tracking tasks, a sur
veillance task and a calculation test (instructions received
through headphones) under time and test stresses. The tasks
included maintaining prescribed speed and attaining differ
ent altitudes and courses in 10 tests. For every test, the num
ber of errors on each instrument together with the number
of correct solutions to the calculations were recorded.
Sleep assessment. Sleep and wake cycles were monitored
using actigraph rdrs'3 this methodology has previously
been successfully used to monitor sleep in United States sol
diers using mefloquine.5 The actigraph used is a commer
cially available activity monitor (Model AMA-32; Ambula
tory Monitoring, Inc., Ardsley, NY). Each wrist monitor
contained a small accelerometric transistor and a low power
microprocessor with digital memory. Activity data were col
lected at 1-mn intervals and stored in digital memory for
later computer retrieval and analysis using ACTION soft
ware (Ambulatory Monitoring, Inc.). Only the nocturnal
sleep episodes were scored. A sleep opportunity period was
identified and analyzed for sleep/nonsleep epochs. The de
vices were worn on the nondominant arm for 24 hr a day
for a baseline period (i.e., no medication used) of three days,
then for four days, including the medication loading dose,
and finally during the last week of the weekly dosage phase.
Sleep length and quality were assessed from motor activity
and immobility during bedtime. Total time asleep, percent
time asleep, and sleep quality were compared between the
loading and weekly mefloquine and placebo administration
phases. Sleep quality was assessed using the Global Index,
which is the sum of the Movement Index and Fragmentation
Index.
The Neurobehavioral Evaluation System (NES). The
NES is a series of computerized tests designed to provide
quantitative neurobehavioral outcomes.'4 This test battery
was used to evaluate psychomotor performance in a study
evaluating mefloquine associated AEs in travelers.'5 A series
of four tests were used: symbol-digit substitution, hand!eye
coordination, visual digit span, and the switching attention
test. After an initial familiarization run, participants per
formed this battery of tests both in the mefloquine phase and
in the placebo phase. The NES scores were then compared
between the mefloquine and placebo groups.
Sway. A simplified postural sway meter force plate was
used to assess balance (Mills M, Communication to the Psy
chological Society, 1994, unpublished data). Three test con
ditions were used: 1) standing with eyes open facing a blank
wall, 2) standing with eyes closed, and 3) standing watching
a real time display of the center of a pressure position on
the screen of a personal computer. In this last situation, sub
jects were asked to keep the center of pressure, shown as a
dot on the screen, as close to the center of the display as
possible. Three 30-sec measurements were made in each test
condition. Mean sway was measured for each individual in
each position. The subjects also completed two standardized
questionnaires.
The Environmental Symptoms Questionnaire (ESQ)
and the Proffle of Mood States (POMS). The ESQ contains
68 questions related to all body 6@7The partici
pant marked a box from one of six graded answers ranging
from not at all to extreme. The second questionnaire, POMS,
contains 65 questions designed to detect six categories of
feelings: tension, depression, anger, vigor, fatigue, and con
fusion. The POMS answers are graded with a five point
score ranging from not at all to@ Total Mood
Disturbance was also assessed.'8 This was calculated by
summing the raw scores across all six moods (tension, de
pression, anger, vigor, fatigue, and confusion) and weighting
vigor negatively. In each study phase, the subjects completed
the questionnaires prior to using medication (baseline), one
day after the loading dose and one day after the final weekly
dose. The ESQ and POMS scores were compared among
baseline, loading dose, and weekly dosing for the mefloquine
and placebo groups. Both the POMS and ESQ have been
successfully used to assess moods and symptoms in previous
studies of the tolerability of mefloquine in both tourist'5 and
military5 populations, and significant differences were found
in POMS and ESQ scores in individuals who experienced
ABs with mefloquine.
Data analysis. The Statistics Package for the Social Sci
ences (SPSS, Inc., Chicago, IL) was used to analyze ICA,
NES, sway meter scores, and sleep parameters. For ICA,
NES scores, and sleep parameters, significance was deter
mined using the Wilcoxon matched pairs signed-rank test (P
= 0.05), which was considered the most appropriate test for
this cross-over study design. Friedman's two way analysis
of variance test was used to assess significance with regard
variableMQ Mean (SD)P Mean (SD)Signifi
cance'
PHeading
(no. of errors)6.24 (6.56)5.58(4.96)NSAltitude
(no. of errors)5.06 (6.55)4.8(4.1)NSSpeed
(no. of errors)1.29 (1.65)1.27(1.44)NSMean
total errors12.58 (11.73)11.65(8.5)NSComputingt
(no. correct)8.09 (1.41)8.55(1.06)NSaNSâ€”notsignificant.t
No. of computingtasks correctlyanswered.
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T@&.n 1
Instrument coordination analyzer scores for mefloquine (MQ) and
placebo (P) phases
puting tasks, users in placebo and mefloquine phases had
almost equivalent scores.
Sleep. With regard to total time spent asleep, the means
of participants taking the mefloquine loading dose (456 mm)
and weekly dose (450 mm) were less than the corresponding
means for those taking the placebo loading (491 mm) and
weekly doses (484 mm) by 35 and 34 mm, respectively (Ta
ble 2). Despite this tendency of mefloquine users to sleep
less than placebo users, no group differences were statisti
cally significant. With regard to percent sleep or the portion
of the actual sleep opportunity period spent sleeping, no sig
nificant differences were observed between mefloquine and
placebo users in either loading or weekly phases. The same
held true for the other parameters: number of awakenings,
average length of awakening, and sleep latency or the num
ber of minutes required for the individual to effectively fall
asleep in the nocturnal sleep opportunity period. Sleep qual
ity, as indicated by the Global Index (lowest value) was best
in the weekly placebo phase but again these differences were
not significant.
Neurobehavioral Evaluation System. There were no sig
nificant differences in NES scores in any test or test subunit
between mefloquine and placebo phases (Table 3).
Postural sway. There was some variation in this param
eter between medication phases for the three positions with
mefloquine users having a higher mean sway (0.24, 0.15,
and 0.33) than placebo users (0.20, 0.15, and 0.26) but no
differences were significant (Table 4).
Environmental Symptoms Questionnaire. A rank or
dering of ESQ symptoms according to mean intensity level
showed a predominance of positive states (e.g., alert, wide
awake) with no significant differences when evaluating the
overall impact of mefloquine versus placebo. However, the
volunteers did report more intense ratings for having diffi
culty sleeping during both the mefloquine loading and week
ly dosing phases; ratings of concentration off were more
intense in the mefloquine weekly phase.
Profile of Mood States. The POMS analysis showed that
the predominant study mood, regardless of medication or
administration phase was one of vigor, a mood pattern typ
ical of the normal, physically active adult. In one patient, a
significant interaction was found for the confusion factor in
the mefloquine weekly administration phase when compared
with other members of the study population, but this was
within the normal range of available standard values. There
were no significant differences in the mood complex scores
for tension, depression, anger, fatigue, and total mood dis
turbance between any of the medication/administration
phases. The moods, with raw scores converted to standard
T scores for comparison, are illustrated in (Figure 1). (A T
to the repeated measurement of sleep parameters over drug
and administration phases. The POMS and ESQ scores were
analyzed using Statistica (StatSoft, Thlsa, OK).
A series of two (mefloquine versus placebo) x three (ad
ministration: baseline versus loading versus weekly) repeat
ed measures analyses of variance (with Tukey post hoc com
parisons as required) were performed on the POMS raw
scores. The ESQ results were similarly analyzed with respect
to intensity scores and symptom clusters for drug and ad
ministration phases. The individual ESQ symptoms were
also analyzed and items selected for their relevance to me
floquine administration were assessed by Cochran's Q test
for related samples.
RESULTS
Spontaneously reported AEs. There was one withdrawal
due to dizziness, diarrhea, and flu-like symptoms and three
volunteers spontaneously reported minor sleep-related AEs
including insomnia, unpleasant dreams, superficial sleep,
and early awakening. These events all occurred in the me
floquine loading dose phase. Two additional events, slight
dizziness and common cold symptoms, were mentioned by
two placebo users on testing day. Analysis of the plasma
samples gave a mean mefloquine concentration of 1,293
ng!ml (range 385â€”2,015 ng/ml) on testing day in users. One
individual had a low concentration of 385 ng!ml and this
was probably due to either poor compliance or interindivi
dual variation in mefloquine pharmacokinetics.
Instrument coordination analyzer. The ICA results
showed no significant differences in the mean number of
errors for the variables heading, altitude, and speed with re
gard to the use of mefloquine or placebo (Table 1). The mean
total number of errors for those in a mefloquine study phase
was slightly greater than the mean summation of those using
placebo (12.58 versus 11.65) but this was not significant.
Similarly, regarding the number of correctly answered com
T@nut 2
Sleep parameters for mefloquine (MQ) and placebo (P) phases
Loading P






Total sleep time (mm) 456 (61)
Percent sleept 97% (3)
Global index (GI)@(sleep quality) 76 (29)
* NS = not significant.
t Portionof sleepopportunityperiodactuallyspent sleeping.
@ Sum of movement index and fragmentation index. Increased 01 indicates poorer sleep quality.
Test type (NES battery)MQ Mean (SD)P Mean (SD)SignificancePSymbol
digit (seconds/digit)1 .79 (0. 18)1 .75(0.15)NSDigit
span forwards (no. correct)8.14 (1.17)8.14(1.13)NSDigit
span backwards (no. correct)7.23 (1.66)7.36 (1.33)NSH d/eye
coordination (log RMSE)1 .64 (0. 16)1.57 (0.13)NSSwitching
attention (side) (msec)203 (24)202(22)NSSwitchi g
attention (direction) (msec)308 (34)306(42)NSSwitchi g
attention (side/direction) (msec)395 (5!)391(46)NSa
NS â€”not significant.
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TABLE 3
Neurobehavioral evaluation system (NES) scores for mefloquine (MQ) and placebo (P) phases
score of 50 [SD = 10] is the norm for adult men and
women. 18)
DISCUSSION
In piloting an aircraft, the need for coordination, concen
tration, psychomotor function, spatial discrimination, and
stress resistance is undoubtably higher than that required in
operating any other vehicle. Furthermore, impairment of per
formance can have disastrous consequences. Measurable al
cohol blood levels have been found in 10â€”30% of pilots
involved in fatal accidents due to pilot error?Â° and this has
led to the development for specific bottle to throttle regula
tions. General aviation fatalities related to pilots' incapaci
tation by psychoactive drugs and medical illness account,
however, for a very low proportion of accidents (< 2%).21
23 \y@@ regard to malaria protection, most air crews rely on
antimosquito measures and the strategy of stand-by treat
ment24 rather than continuous use of antimalarial agents. The
antimalarial chloroquine is allowed for cockpit crews despite
the provision that it may cause blurring of vision and diz
ziness.' Persons so affected are advised to switch to another
prophylactic drug. Should mefloquine chemoprophylaxis be
an option for crews operating for longer periods in areas of
high risk of chioroquine-resistant Plasmodium falciparum?
The primary objective of this study was to assess whether
or not mefloquine, at prophylactic concentrations, impaired
performance in the ICA and NES tests. Although perfor
mance assessment is the main thrust of the study, we de
signed our test battery to consider a broad range of AEs such
as sleep disruption, mood changes and others because ulti
mately these peripheral AEs may impact performance.
The average level of ICA scoring attained in the study
was high, which is typical for trainee pilots because they
have retained a familiarity with the apparatus from recruit
ment to the Aviation School. The ICA test has previously
been shown to be sensitive to drug-induced performance
changes in pilots as demonstrated in a study of the residual
T@mn 4
Postural sway (degrees) for each test situation in mefloquine (MQ)
and placebo (P) phases




a NS â€”not significant.
effects of the hypnotics midazolam and triazolam versus pla
cebo.'2 Our results show that the mean number of errors for
each of the variables heading, altitude, and speed do not
differ significantly between mefloquine and placebo users.
A further test of psychomotor performance used the NES
test. This computer-driven test battery has previously been
used to demonstrate impaired performance in groups cx
posed to neurotoxicants.@27 All candidates performed well
during NES tests in both medication phases with no signif
icant difference seen for either group in any test or subtest.
The ICA and NES results show that mefloquine, at steady
state, does not adversely influence performance in individ
ual@ with no AEs. It is unclear whether or how the param
eters measured would change if a participant had AEs. The
impact on performance would depend on the severity of the
AE and on the individual's compensating abilities. Other
studies show that those who experience mild AEs with me
floquine are not adversely affected with regard to their per
rm'5 Nevertheless, even if no adverse performance
effects were detected in this study, it remains possible that
idiosyncratic responses may occur. Further studies are need
ed to measure broader aspects of performance including the
addition of diverse tasks such as radio-frequency signal
tracking, airport traffic control vectoring, traffic observation,
visual reaction time in night flying, and performance
changes at high altitudes and during whole-body motion.
The greater challenge is, however, to try to pinpoint the rare
pilot who may experience neuropsychiatric AEs and to date,
apart from obvious risk groups, such as those individuals
with with a personal or family history of epilepsy or psy
chiatric disorder or those who abuse alcohol or recreational
drugs, it has proven impossible to predict who will have such
an event.
For the tourist using mefloquine, this performance issue,
especially with regard to driving a car, has implications. In
a recent study, Vuurman and others28 assessed the effect of
mefloquine prophylaxis, with and without an alcohol chal
lenge, on actual car driving performance in healthy volun
teers. The study design and dosage regimen were similar to
the present study. Driving (road tracking and car following
tests) was not impaired by mefloquine (versus placebo), with
and without the alcohol challenge (blood alcohol concentra
tion 0.3â€”0.5mg/ml). The investigators concluded that me
floquine did not impair coordinated psychomotor activities
necessary for safe driving.
Sleep disruption has been reported during prophylactic use
of anti-malarials. In a study of short-term travelers, users of
a chloroquine plus proguanil regimen reported a higher in
MQ
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FIGuan 1. Mean mood scores for each medication and administration phase. P = placebo; MQ = mefloquine.
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Behavioural aspects of travellers in their use of
malaria presumptive treatment
P. Schlagenhauf,' R. Steffen,2 A. Tschopp,3 P. Van Damme,4 M.-L. Mittelholzer,5
H. Leuenberger,6 & C. Reinke7
The use of stand-by treatment for malaria by travellers depends on their knowledge, attitudes and be-
haviour. We examined the behavioural aspects of a cohort of travellers from Switzerland to low-risk
malarial areas who, on recruitment, were provided with a kit containing medication for stand-by treat-
ment, guidelines on the diagnosis of malaria, and materials for collection of blood samples for later con-
firmation of malaria. All subjects were urged to seek medical advice at the first signs of possible malar-
ial symptoms.
Illness (fever as the main indicator) was reported by 123 of the 1187 participants, often accompa-
nied by shivering/chills (36.6%), headache (35.0%), gastrointestinal symptoms (69.9%), and myalgia
and/or arthralgia (41.5%). Two-thirds of those ill failed to seek medical attention despite their symptoms
and pretravel advice. Only 9 (7.3%) were actually beyond the reach of medical attention. The stand-by
treatment was self-administered by 6 travellers, only one of whom had confirmed malaria. Two non-
serious adverse events were reported. All users consulted a physician after administering the presump-
tive treatment. This stand-by approach is limited by inappropriate behaviour and poor malaria aware-
ness among travellers. These negative factors can be mitigated by development of an improved kit con-
taining a simple test for self-diagnosis.
Introduction
More than 10 000 travellers every year fall ill with
malaria and the case fatality rate in infections due to
Plasmodium falciparum varies between 0.4% and
8.7% (1-3). Both the World Health Organization (4,
5) and the U.S. Centers for Disease Control (6)
recommend that in addition to, or sometimes instead
of chemoprophylactic drugs, travellers to malaria-
endemic areas may carry with them suitable medica-
tion for presumptive or stand-by treatment (SBT) for
emergency use when malaria is suspected and medi-
I Division of Communicable Diseases, Institute for Social and
Preventive Medicine, University of Zurich, Sumatrastrasse 30,
8006 Zurich, Switzerland. Requests for reprints should be sent
to Dr Schlagenhauf.
2 Professor and Head, Division of Communicable Diseases,
Institute for Social and Preventive Medicine, University of Zurich.
3Statistician, Division of Biostatistics, Institute for Social and
Preventive Medicine, University of Zurich.
4Research Assistant, Department of Epidemiology and Commu-
nity Medicine, University of Antwerp, Antwerp, Belgium.
5 Tropical Medicine Unit, F. Hoffmann La Roche, Basle, Switzer-
land.
6 Professor and Head, Institute of Pharmacy, Basle, Switzer-
land.
7Institute of Pharmacy, Basle, Switzerland.
Reprint No. 5589
cal help is unavailable. This altemative is envisaged
primarily for travellers to remote malarious areas
where access to diagnostic and therapeutic facilities
is limited. The rationale behind this recommendation
is that in areas of low transmission the risk of ad-
verse events attributed to chemoprophylaxis (sup-
pressive therapy) exceeds the benefit of avoided in-
fections (7). Presumptive treatment can be life-saving
since falciparum malaria in a non-immune traveller
requires prompt treatment.
Knowledge of, attitudes towards and practices of
stand-by treatment are poorly documented. There is
some information on the use of presumptive therapy
by travellers (8) and airline crews (9, 10). Data on
associated problems such as treatment failures (11),
inappropriate use for non-malarial fevers, and inci-
dence of adverse events are scarce. There is very
little information on the behavioural aspects of trav-
ellers who are prepared for stand-by treatment,
including the geographic location, type and timing of
symptoms, chronological sequence of events, avail-
ability of medical help, compliance, medical follow-
up and final outcome. We therefore conducted a
longitudinal study to elucidate the behavioural char-
acteristics of travellers with regard to the use of ma-
larial stand-by treatment. Volunteers were followed
by questionnaire and serologically using blood sam-
ples from the fingertip.
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Materials and methods
Selection of subjects. All travellers, who could nor-
mally be recommended to carry stand-by treatment
with them according to Swiss guidelines (12), were
invited to take part in a cohort study at the Vaccina-
tion Centre of the Institute for Social and Preventive
Medicine, University of Zurich, between March and
November 1992. Their destinations were predomi-
nately areas of Central and South America or desti-
nations in Asia (Fig. 1). The nature of the study was
fully explained to each potential volunteer, who
entered the study by giving written informed
consent. Excluded from the study were pregnant or
nursing women, persons with a history of allergy or
severe reaction to components of the trial medica-
tion, and those with a history of epilepsy or psychi-
atric disorder. Long-term travellers (sojoums of
more than six months) were excluded due to follow-
up difficulties.
Materials. Each volunteer was provided with a kit
containing the stand-by treatment which, as recom-
mended by Swiss experts in 1992, was the triple
combination called Fansimef (mefloquine 250 mg,
sulfadoxine 500 mg, and pyrimethamine 25 mg). A
single administration of three Fansimef tablets was
the recommended dose for persons with a body
weight >45 kg in cases of suspected malaria. The
front of the kit contained concise information on
how to recognize malarial symptoms and what pro-
cedure to follow if the condition were suspected.
Appropriate use of the medication was defined as a
single dose of 3 tablets of Fansimef administered if
all of the following were applicable:
the traveller was unwell with fever (37 °C on two
readings taken at least 2 hours apart) with or
without headache and/or myalgia;
Fig. 1. Number of travellers and their destinations.
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- at least 6 days had elapsed since the traveller
entered the endemic area; and
- medical attention was unavailable within 12
hours of the illness. After this presumptive treat-
ment it was stressed as imperative that the travel-
ler should visit a physician as soon as possible to
confirm the presumptive diagnosis.
A thermometer in a protective case was also
provided, together with material (cotton swabs and
lancets) for sampling fingerprick blood (50 pl) and
chromatography paper that was clearly demarcated
into three imprinted circles: one each to contain the
blood droplet on recruitment, when malarial infec-
tion is suspected but before medication is adminis-
tered, and after return to Switzerland irrespective of
whether malarial treatment had been administered.
This last sample was to be collected at least four
weeks after the return date to ensure that any malar-
ial cases occurring in this time frame were included
in the study. Thus, each volunteer provided at least
two blood samples, by fingerprick, which were spot-
ted directly onto the chromatography paper.
Each volunteer also received a questionnaire
concerned with the following:
- data on the traveller and his/her destination and
type of sojourn;
- data in cases of illness with fever;
- data when presumptive treatment was adminis-
tered; and
- data on medical consultations, malaria tests and
differential diagnoses.
A stamped addressed envelope was provided for
return of the questionnaire, the chromatography
paper blood samples, and unused medication. In ad-
dition, a postcard was included in the kit (to be
retained by the traveller for six months after return)
in case malarial symptoms or delayed adverse events
appeared later than one month after return. Written
reminders were mailed to those who failed to return
the questionnaires and blood samples as instructed.
Analysis of blood samples. The blood samples, elu-
ted from the chromatography paper, were analysed
using enzyme-linked immunosorbent assay (ELISA)
for the presence of IgM and IgG antibodies to the
synthetic peptide (NANP)50, which represents the
immunodominant central repeat region of the major
surface protein of P. falciparum sporozoites. Earlier
work (13) suggests good sensitivity with this method
but to ensure complete detection, the paper samples
were later re-tested using the polymerase chain reac-
tion (PCR) (14-16). PCR amplification was carried
out on a polymorphic region of the major merozoite
surface protein 1 (MSPI) of both P. falciparum and
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P. vivax (17, 18). Cases of malaria were included
only if confirmed by a positive ELISA or a positive
PCR, or microscopically from blood smears obtained
by the physician consulted when malaria was sus-
pected. Persons who were treated presumptively but
remained unconfirmed were considered to be non-
malarial cases.
Statistical analysis. Data were analysed using the
SPSSPC software package. The relationship between
use of stand-by treatment and other variables was
analysed using the chi-squared test and testing
Kendall's X coefficient. Significance was defined as
P<0.05.
Results
A total of 1572 volunteers (approximately half of all
who received stand-by treatment at the vaccinating
centre in the specified period) were recruited, of
which 1187 (76%) were evaluated. The remaining
volunteers (24%) failed to return their questionnaires
despite reminders or were lost to follow-up. The
demographic data are shown in Table 1. The dura-
tion of the travellers' sojoum varied from less than
one week to periods of up to six months. The volun-
teers were exposed for 4918 weeks in the low-risk
malaria endemic areas. A total of 123 subjects
(10.4%) reported that they had been ill with fever
during their trip or in the month after retum. Addi-
tionally, 14.2% were ill without fever or had some
form of minor accident, and 73.5% of all partici-
pants regarded themselves as healthy throughout the
entire sojourn. The relationship between the travel-
ler's sex and incidence of illness was not significant
(P=0. 12). Younger travellers (aged <30 years) tended
to classify themselves as ill more often than older
travellers. This difference was significant (P<0.01).
The first group, those reporting illness with fever,
were further investigated since fever was one of the
prerequisites for presumptive malarial treatment.
Symptoms, concomitant with the fever, which could
be ascribed to malaria included shivering/chills
(36.6%), headache (35.0%), gastrointestinal symp-
toms (69.9%), and myalgia and/or arthralgia (41.5%)
(Fig. 2).
Behaviour in response to illness. In reply to the
question: "When did you first suspect malarial infec-
tion?", 7 (5.6%) of the 123 persons with fever sus-
pected malaria before day six of their trip while 41
(33.3%) contacted a physician within the specified
time-frame of 12 hours (including 12 (9.8%) who
contacted a doctor but could not obtain a consulta-
tion within 12 hours). A total of 82 travellers
(66.6%) failed to seek medical attention despite their
Table 1: Demographic data on the 1187 participants in
the study
Characteristic % Characteristic %
Age group (years): Duration of stay:
<20 1.2 <1 week 5.6
20-29 47.4 2 weeks 17.4
30-39 26.4 3 weeks 29.7
40-49 12.0 4 weeks 27.5
50-59 8.1 -2 months 11.2
.60 3.9 3-6 months 6.0
Unknown 1.0 Unknown 2.5
Sex: Place of staya
Male 50.4 Mainly in cities 23.3
Female 48.6 Mainly in towns/









a More than one answer possible.
symptoms. This category included 9 persons (7.3%)
who did not consult a physician as they were out of
reach of medical attention.
Of those who received medical attention, the
time interval from onset of symptoms to medical
consultation was in 95% of cases less than 4 days
(range, 4 hours to 30 days; mean, 44 hours), and
59.1% of those who tried did manage to receive
medical attention within 12 hours. The behaviour in
reaction to perceived illness did not vary significant-
ly with age or sex although there was a trend show-
ing that women were more compliant with the issued
instructions than men.
Fig. 2. Percentage distribution of symptoms In 123







.Diarrhoea Chills Headache Myalgia Vomiting Others
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Influence of education. Those with higher education
(university level) were less likely to consider them-
selves ill with fever and possible malarial symptoms
than the other travellers (P<0.01). Those with a
lower educational status were more correct in their
behaviour and their reaction to illness (P=0.01). In
general, the lower the level of education the greater
the likelihood that the traveller would seek medical
attention when ill.
Users of presumptive treatment. Only six persons,
three women and three men, actually used the thera-
py for suspected malarial symptoms after the 6th day
abroad. This accounts for 0.5% of the complete
study population and also for a small proportion
(4.6%) of those in the "ill with fever" group. The
characteristics of the six users are shown in Table 2.
All users of the medication complied with the dosage
instructions and administered the three Fansimef tab-
lets as a single dose. Two travellers self-adminis-
tered their medication back home in Switzerland on
the advice of their doctor. The time required for
fever clearance ranged from 1 to 3 days. All users
consulted a doctor after the administration of the
medication to check the presumptive diagnosis; in
some cases, medication other than the antimalarial
agents was prescribed. Only one of the users actually
had a malarial infection (confirmed by blood smear).
Adverse events. Subjective adverse events were
experienced by two of the six Fansimef users: one
case of subjectively severe dizziness resulting in 2
days incapacitation (bed rest required) was reported.
The other event was insomnia, lasting for two nights.
Fig. 3. Imported malaria cases from Thailand among
Swiss travellers, 1983-92, using chemoprophylaxis (till
1988) and stand-by treatment (from 1989).
Discussion
The participants in this study all travelled to classi-
fied low-risk areas where the probability of contac-
ting a malarial infection during a limited time period
is minimal. The soundness of the antimalarial strategy
adopted by the Swiss (i.e., no chemoprophylaxis, but
prepared for stand-by treatment) during travel to
low-risk areas is demonstrated by the fact that the
number of imported malaria cases from areas, such
as Thailand, has not increased since this strategy was
introduced in the autumn of 1988 (Fig. 3). There are,
however, problems inherent in the strategy as shown
in our study. Diagnosis of malaria is difficult, even
for medical professionals and it is likely that trav-
Table 2: Characteristics of six travellers who used stand-by treatment for presumptive malaria
Age/sex Area Onset of Physician Fever
(years) of use Symptoms symptoms consulted Diagnosis clearance in:
User 1 26/F Colombia Fever, headache, Day 17 Out of reach Gastritis 3 days
myalgia, diarrhoea,
vomiting
User 2 38/M Switzerland Fever, headache, Day 24 Yes Malaria 3 days
(returned from chills, myalgia (confirmed by
Malaysia) microscopy)
User 3 28/F Hong Kong Fever, headache, Day 20 Yes Viral infection 2 days
(on arrival from chills, myalgia
Indonesia)
User 4 58/M Switzerland Fever, diarrhoea, >Day 7 Yes Amoebiasis 2 days
(on return from vomiting
Indonesia)
User 5 28/M Sarawak Fever, shivering, Day 17 Yes (twice) Viral fever 1 day
(Malaysia) myalgia, headache, (dengue
diarrhoea, vomiting fever)
User 6 29/F Nepal Fever, diarrhoea, Day 6 Yes Viral infection 1 day
headache, vomiting,
shivering, myalgia
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ellers may mistake influenza or some other febrile
illness for malaria and use the stand-by treatment.
In this study, 123 persons (10.4%) judged their own
clinical symptoms, with "malaria" as one possible
diagnosis. Six persons used the stand-by treatment
(0.5% of the entire cohort or 5% of those with pos-
sible malarial symptoms), but only one had con-
firmed malaria. On the other hand, some persons
with typical malaria symptoms (82 (66.6%) of those
ill) often hesitate to use the treatment-and a few
of them may really have malaria. Thus, while
wrong use of stand-by treatment may lead to serious
adverse effects, failure to use it could result in
death due to malaria.
The efficacy of the medication as a stand-by
treatment cannot be assessed from this study, but
travellers to areas of multiple-drug resistance (such
as the border areas of Thailand) should be aware that
the use of emergency malarial treatment in such
areas could act as a short-term febrifuge and symp-
tom suppressant without a cure, so that prompt medi-
cal attention is always imperative (8).
The inappropriate use of stand-by treatment may
expose persons without malaria to a significant drug
risk. With mefloquine, for example, which is often
used alone as a stand-by treatment, the incidence of
psychiatric events in prophylaxis is rare (approx. 1 in
13 000), but neurotoxicity is approximately sixty
times more probable after treatment than with pro-
phylactic use (19). Another drug for presumptive
therapy, halofantrine, has been associated with elec-
trocardiographic changes, namely prolongation of
the QTc interval (20-23). In our study, none of the
users experienced a serious adverse event; the ad-
verse events reported were probably due to the
mefloquine component of Fansimef. Such events
have been reported elsewhere (24-26).
The behaviour of travellers is unpredictable.
Tourists despite being made aware of the urgency of
malarial treatment in this study, as elsewhere (27),
waited for their symptoms to resolve spontaneously.
This was contrary to the prescribed advice. The
majority of travellers to Asia and South America can
consult a physician if they suspect malaria; only 9
(7.3%) of those with fever in our study considered
themselves out of reach of medical attention. Stress
should thus be placed on seeking medical attention
locally, whenever possible in case of illness. The
importance of immediate follow-up consultation
after stand-by treatment should also be underlined to
determine the accuracy of the presumptive diagnosis,
the need for alternative antimalarials in cases of non-
efficacy of this treatment, and other treatment in
cases of erroneous self-diagnosis.
Instructions to travellers should be given orally
and in writing, including details of the type and
severity of possible malarial symptoms and the cir-
cumstances in which the use of stand-by treatment
can be considered. A possible future development is
a kit which will enable the traveller to test a blood
droplet for possible malarial infection using a simple
diagnostic technique such as the rapid manual test
"paraSight-F", an antigen capture test which is
simple to perform and provides a definitive answer
(88.9% sensitivity) in approximately ten minutes
(28).a Such a test, appropriately simplified for use by
travellers, would reduce the risk of a wrong diagno-
sis of malaria and enhance the strategy of presump-
tive treatment. Self-diagnosis of other frequently
occurring illnesses among travellers (e.g., diarrhoea)
is comparatively easier because the symptomatology
can be clearly defined, but in malaria the clinical
symptoms are often mild and atypical. Provision of a
diagnostic test would increase the cost of the SBT
strategy. A small additional charge may be accept-
able compared with the overall cost of travel to dis-
tant places.
Our results showed only one case of confirmed
malaria in a population of 1572 travellers, which is
similar to previously reported attack rates for low-
risk areas (8). The intervention costs incurred with
the single malaria case in this study were approxi-
mately Sw.fr. 44000 (approximately US$ 32 000)
(i.e., 1572 times the cost of the kit (Sw.fr. 23), plus
41 visits to doctors (Sw.fr. 169 each) and six addi-
tional follow-up visits). The visits are at Swiss
prices, which in developing countries would cost
less. The benefits of this intervention strategy are the
prevention of malarial complications. The approxi-
mate costs incurred in various outcomes of malarial
infections, including death, have- previously been
estimated by Dinkel et al. (29). The addition of a
simple diagnostic kit to the stand-by treatment
would increase the intervention cost but would re-
duce the potential for misdiagnosis and inappropriate
treatment. Travel to areas with greater malaria
attack rates and the possibility of carrying the kit on
more than one trip (prolonged expiry dates) would
enhance the cost-effectiveness of this development.
In summary, the advantages of the stand-by
treatment approach are the avoidance of side-effects
associated with chemoprophylaxis and the life-
saving potential of having presumptive therapy for
falciparum infections. One constraint is the wide
range of clinical presentations of malaria which
makes it difficult to define simple guidelines with
a Peyron F et al. Assessment of a rapid manual test for the
diagnosis of Plasmodium falciparum malaria (Poster). In: Pro-
ceedings of the 3rd Conference on International Travel Medi-
cine, 26-29 April 1993, Paris.
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accurate indications for the safe and appropriate use
of antimalarial drugs by travellers. As the diag-
nosis of malaria is unlikely to be correct, stand-by
treatment is more often overused or underused than
used correctly. Incorrect use may actually be danger-
ous (30). Travellers should be encouraged to use
adequate anti-mosquito measures and to visit a local
physician if symptoms occur. Education of the travel-
ling public and increasing their understanding of
malaria prevention and cure are top priorities. In
addition, there is an urgent need for development of
a kit containing a test for rapid self-diagnosis by
evaluation of a blood droplet. The aim therefore
should be refinement of the strategy with the ad-
dition of a test for self-diagnosis.
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Resume
Aspects comportementaux de l'utilisation
du traitement pr6somptif du paludisme
par les voyageurs
Les connaissances, les attitudes et les pratiques
des voyageurs en ce qui concerne le traitement
de r6serve (SBT) du paludisme sont mal docu-
mentees. Cette 6tude examine le comportement
d'une cohorte de voyageurs en provenance de
Suisse et se rendant dans des r6gions d'end6mie
palustre a faible risque, qui avaient adopt6 les
mesures antimoustiques comme strat6gie de pr6-
vention du paludisme et qui avaient emport6 un
traitement de r6serve a utiliser en cas de besoin.
Les sujets ont 616 recrut6s entre mars et
novembre 1992; il leur a ete distribu6 un n6ces-
saire contenant un traitement m6dicamenteux de
r6serve (m6floquine, sulfadoxine et pyrimethami-
ne), un thermom6tre m6dical, des informations sur
le diagnostic du paludisme, et un mat6riel de pre-
I6vement de sang capillaire au bout du doigt en
vue de la confirmation ult6rieure de l'infection.
Tous ces sujets ont 6t6 instamment invit6s a con-
sulter un medecin d6s les premiers sympt6mes
pouvant evoquer un paludisme. Sur les 1187 parti-
cipants, 123 ont signal6 une maladie (la fi6vre
6tant le principal indicateur), avec frissons (36,6%),
c6phal6es (35%), troubles digestifs (69,9%), myal-
gies etlou arthralgies (41,5%). Les deux tiers des
sujets tomb6s malades n'ont pas consult6 de
medecin, malgre leurs sympt6mes et les conseils
regus; seuls 9 d'entre eux (7,3%) etaient reel-
lement hors de port6e de tout traitement m6di-
cal. Six voyageurs ont pris leur traitement de
reserve, mais un seul etait atteint de paludisme
confirm6. Tous les utilisateurs ont consulte un
medecin apres la prise du traitement pr6ventif, et
deux r6actions indesirables sans gravit6 ont ete
signalees.
La strategie du traitement antipaludique de
reserve permet d'eviter les effets ind6sirables
associ6s a la chimioprophylaxie et a l'avantage
d'utiliser des medicaments capables de sauver le
malade en cas d'infection a falciparum. 11 est tou-
tefois peu probable que le diagnostic de paludis-
me soit correct, et le traitement de reserve est
plus souvent sur- ou sous-utilise que correctement
utilis6. Cette strategie est donc limitee par le com-
portement des voyageurs, le manque de connais-
sances concernant le paludisme et la difficult6 de
savoir s'il faut prendre ou non le traitement. Une
solution possible pourrait etre de mettre au point
un n6cessaire qui permettrait au voyageur de faire
lui-meme, au moyen d'une technique simple, le
diagnostic de paludisme sur une goutte de sang
pr6lev6e au bout du doigt.
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